4100: Cellular Therapy Essential Data Follow-Up

This form must be completed for all recipients of cellular therapy (non-HCT), including post-HCT DCI infusions. For recipients of hematopoietic cellular transplants, complete the appropriate HCT follow-up form. For recipients of Donor Lymphocyte Infusions (DLI), complete the Donor Lymphocyte Infusion (2199) form.

The Post-Cellular Therapy Essential Data (Post-CTED) follow-up form focuses on key follow-up information for each reporting period, including the survival status of the recipient, causes of death if the recipient died in the period since the last report, additional cellular infusions performed, response to the cellular therapy, relapse, current hematologic findings, development of new malignancies, persistence of the cellular product (product specific), development and severity of toxicities (e.g. cytokine release syndrome, neurotoxicity), infection and fertility information.

The Post-CTED Form must be completed at the following time points post-cellular therapy: 100 days, six months, and annually thereafter. The follow-up reporting schedule is determined by whether the product is genetically modified or not. The structure of the Post-CTED is such that each form should fit on a timeline with distinct start and stop dates that do not overlap any other forms.

**Combined follow up**

In scenarios where both HCT and cellular therapy forms are being completed, there are two scenarios where the Cellular Therapy Essential Data Follow-Up (4100) form is completed:

**Example 1.** Cellular therapy after HCT: completion of this form should be based on the time period in relation to the CT infusion date (i.e., 100 days after the CT infusion date). The visit ID and date of contact should match between the corresponding Post-HSCT Data (2100) or Post-Transplant Essential Data (2450).

**Example 2.** HCT after cellular therapy: completion of this form should be based on the time period in relation to the HCT infusion date (i.e., 100 days after the HCT infusion date). The visit ID and date of contact should match between the corresponding Post-HSCT Data (2100) or Post-Transplant Essential Data (2450).

Duplicate questions between HCT and cellular therapy forms may be disabled on the Post-CTED. A full list of enabled/disabled fields can be found on the “Subsequent Infusions – Updates to Follow-Up Reporting” section of the Data Management Guide. Illustrations of the combined follow up scenarios can also be found in the Guide.

**Links to sections of form:**
- Q1: Product
- Q2-3: Survival
- Q4-8: Subsequent Cellular Infusions
- Q9-11: Best Response to Cellular Therapy
- Q12-20: Peripheral Blood Count Recovery
Q21-22: Disease Relapse or Progression
Q23-33: Current Hematologic Findings
Q34: New Malignancy, Lymphoproliferative or Myeloproliferative Disease/Disorder
Q35-59: Persistence of Cells
Q60-79: Graft vs. Host Disease
Q80-170: Toxicities
Q171-175: Infection
Q176-177: Pregnancy Status

Manual updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

<table>
<thead>
<tr>
<th>Date</th>
<th>Manual Section</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/6/2023</td>
<td>4100 Post-CTED</td>
<td>Modify</td>
<td>Increased the length of time required to report resolution of hypogammaglobulinemia from 3 months to 6 months without the need for IVIG infusions. Added a 5th example.</td>
</tr>
<tr>
<td>2/20/23</td>
<td>4100 Post-CTED</td>
<td>Modify</td>
<td>Updated the applicable response options for non-malignant disease in Table 1: Complete Response, Partial Response, or No Response Normalization of organ function, Partial normalization of organ function, No response, Worsening of organ function</td>
</tr>
<tr>
<td>2/15/2023</td>
<td>4100 Post-CTED</td>
<td>Add</td>
<td>The ‘No Documentation of Contact Date’ red warning box added above Q2: No Documentation of Contact Date The contact date data field cannot be left blank and is required to be reported. In cases where the recipient passed away and there is no documentation to report the date of death, the guidelines for reporting estimated dates must be used.</td>
</tr>
<tr>
<td>2/7/2023</td>
<td>4100 Post-CTED</td>
<td>Modify</td>
<td>Added Carvykti™ to the red warning box below question 180: This question will enable only if the commercially available product Kymriah®, Breyanzi™, Abecma®, or Carvykti™ is selected in question 1 and can only be completed on the 100 day and 6 month follow-up forms.</td>
</tr>
<tr>
<td>2/3/2023</td>
<td>4100 Post-CTED</td>
<td>Modify</td>
<td>Clarified what should not be reported as CRS therapy, highlighting the follow text in a blue box: Supportive care treatments should not be reported as treatment for CRS. Examples of what not to report as other therapy include, but are not limited to, acetaminophen (Tylenol®) albumin, antibiotics, IV fluids, or any brand name or specific corticosteroids administered.</td>
</tr>
<tr>
<td>12/12/2023</td>
<td>4100 Post-CTED</td>
<td>Modify</td>
<td>Clarified when to report other grade 4 organ toxicities/symptoms: If Other is selected, then the grade 4 toxicities / symptoms that are reported should be</td>
</tr>
<tr>
<td>Date</td>
<td>Code</td>
<td>Action</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td>related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.</td>
</tr>
<tr>
<td>12/12/2022</td>
<td>4100</td>
<td>Modify</td>
<td>Clarified when to report other grade 3 organ toxicities/symptoms: <strong>If Other is selected, then the</strong> grade 3 toxicities / symptoms that are reported should be related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.</td>
</tr>
<tr>
<td>11/15/2022</td>
<td>4100</td>
<td>Modify</td>
<td>Clarified how to report a fever documented from a home test: <strong>Fever</strong>s (≥100.4°F or ≥38°C): A disorder characterized by elevation of the body’s temperature above the upper limit of normal. Do not report fever if less than 100.4°F or 38°C in this field. Fever less than 100.4°F or 38°C does not qualify as a symptom of CRS. Report the date of fever onset in question 87. If there were multiple fevers in the reporting period, report the first occurrence. <strong>If the recipient self-reported a fever from a home test, and the date is documented in the medical records, report the date of the home test.</strong></td>
</tr>
<tr>
<td>10/17/2022</td>
<td>4100</td>
<td>Modify</td>
<td>Updated the continue with question number: If the reason for the new course of cellular therapy was <strong>Failure to respond or in response to disease assessment</strong> or for a <strong>New indication</strong>, continue with question 10 6 to report the event date.</td>
</tr>
<tr>
<td>10/10/2022</td>
<td>4100</td>
<td>Modify</td>
<td>Clarified in questions 92-94 what not to report for other CRS therapy (in red): Examples of what not to report as other therapy include, but are not limited to, acetaminophen (Tylenol®) albumin, antibiotics, IV fluids, or any brand name or specific corticosteroids administered.</td>
</tr>
<tr>
<td>10/10/2022</td>
<td>4100</td>
<td>Modify</td>
<td>Clarified in questions 95-105 what not to report for other hypotension therapy (in red): Examples of what not to report as other therapy include, but are not limited to, acetaminophen (Tylenol®) albumin, antibiotics, IV fluids, or any brand name or specific corticosteroids administered.</td>
</tr>
<tr>
<td>9/23/2022</td>
<td>4100:</td>
<td>Modify</td>
<td>Updated for new DLI reporting process: This form must be completed for all products for recipients of non-HCT cellular therapy (including post-HCT DCI / DLI infusions). For recipients of hematopoietic cellular transplants (HCT), complete the Hematopoietic Stem Cell Transplant (HCT) Infusion (2006) form. For recipients of Donor Lymphocyte Infusions (DLI), complete the Donor Lymphocyte Infusion (2199) form.</td>
</tr>
<tr>
<td>4/11/22</td>
<td>4100</td>
<td>Add</td>
<td>Clarification added on reporting COVID-19 infections for subsequent infusions &amp; possible reporting scenarios: <strong>Do NOT report an infection in the following scenarios:</strong> A recipient only has a positive antibody result. The recipient was symptomatic and treated but COVID-19 diagnostic testing was not performed and / or COVID-19 diagnostic testing was performed and</td>
</tr>
</tbody>
</table>
DO report an infection in the following scenarios:
A recipient has a positive COVID-19 diagnostic result (PCR or antigen) or if treatment was given or if the recipient was asymptomatic.
A recipient has a positive antibody result and a positive COVID-19 diagnostic test (PCR or antigen)

<table>
<thead>
<tr>
<th>Date</th>
<th>Code</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/11/2022</td>
<td>4100 Post-CTED</td>
<td>Add</td>
<td>COVID-19 Reinfection blue box added above Q204-208: Reporting COVID-19 Reinfection: There have been cases of recipients recovering from COVID-19 infection, only to later test positive again. For CIBMTR purposes, a new COVID-19 infection should be reported when a recipient tests positive again &gt;21 days from resolution (resolution defined as no signs or symptoms of infection, or a negative diagnostic test).</td>
</tr>
<tr>
<td>4/11/2022</td>
<td>4100 Q204-213: Infection</td>
<td>Add</td>
<td>COVID-19 Reinfection blue box added above Q204-208: Reporting COVID-19 Reinfection: There have been cases of recipients recovering from COVID-19 infection, only to later test positive again. For CIBMTR purposes, a new COVID-19 infection should be reported when a recipient tests positive again &gt;21 days from resolution (resolution defined as no signs or symptoms of infection, or a negative diagnostic test).</td>
</tr>
<tr>
<td>4/11/2022</td>
<td>4100 Q204-213: Infection</td>
<td>Add</td>
<td>Clarification added in regard to revaccination post-infusion: Indicate if the recipient received a vaccine for COVID-19 (one dose without a planned second dose, first dose with planned second dose, second dose, third dose, and/or booster dose) within the current reporting period. If the recipient did not receive a vaccine for COVID-19 or it is not known if the recipient received a vaccine, select No or Unknown, respectively, and continue with question 214. <strong>Revaccination Post-Infusion</strong>: When vaccines are given post-infusion, the physician should make the determination on whether the doses are part of the primary series of vaccines, third primary dose, boosters, or revaccination. If a recipient receives a new course of COVID vaccines following infusion as revaccination, report the vaccines as a new series. The most up to date CDC COVID-19 vaccine information for immunocompromised people can be found here.</td>
</tr>
<tr>
<td>4/11/2022</td>
<td>4100 Q204-213: Infection</td>
<td>Modify</td>
<td>Updated blue box above Q210-211 how to report multiple vaccine doses: <strong>COVID-19 Vaccine Doses</strong> FormsNet3SM application: Complete questions 210 – 213 to report all COVID-19 vaccine doses received in the current reporting period by adding an additional instance in the FormsNet3SM application. A separate instance should be added for each dose.</td>
</tr>
<tr>
<td>4/11/2022</td>
<td>4100 Q204-213: Infection</td>
<td>Modify/Add</td>
<td>Updated question instructions: For the reported dose, specify the vaccine brand the recipient received. If the vaccine brand is not listed, select <strong>Other</strong> type and specify. If the vaccine brand is unknown, leave the field blank and override the error as <strong>Unknown</strong>. Third dose versus Booster dose blue box added above</td>
</tr>
</tbody>
</table>
question 210-211: Third dose versus Booster dose: To determine between a third dose and a booster dose, seek clinician clarification, as needed, using the guidelines listed below:

Third dose: An additional primary dose required for recipients who did not build enough protection from their primary vaccine series, typically for immunocompromised individuals.

Booster dose: Administered to recipients who have enough protection after completing their primary vaccine series but then protection decreases over time.

Primary vaccine series: Two doses of Pfizer-BioNTech or Moderna One dose of Johnson & Johnson’s Janssen.

<table>
<thead>
<tr>
<th>Date</th>
<th>Section</th>
<th>Action</th>
<th>Change Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/11/2022</td>
<td>4100: Q204-213: Infection</td>
<td>Modify</td>
<td>Updated question instructions: For the reported dose, specify the vaccine dose the recipient in the current reporting period and specify the date when the dose was received.</td>
</tr>
<tr>
<td>4/11/2022</td>
<td>4100: Q89-202: Toxicities</td>
<td>Add</td>
<td>Additional example (#5) added to clarify hypogammaglobulinemia reporting: Example 5. For an adult recipient, IgG levels were below 600 mg/dL pre-infusion and immunoglobulin replacement therapy (IVIG) was given pre-infusion. Post-infusion, all IgG values were greater than 600 mg/dL and never dropped below 600 mg/mL. This is not reported as a toxicity since the IgG levels were never below 600 mg/dL after infusion.</td>
</tr>
</tbody>
</table>
Q1: Product

Question 1: Name of Product: (for most recent cell therapy infusion)

The name of the product reported will be auto populated with the value reported on the Pre-Cellular Therapy Essential Data (4000) form. If the cellular therapy product infused is a commercially available or pre-commercial product, this question is used to enable questions related to toxicities and disable questions that do not apply.

Combined follow up
In scenarios where both HCT and cellular therapy forms are being completed, and the recipient has received the HCT after the cellular therapy, the product name should be for the prior cellular therapy product.

Section Updates:

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7/29/2021</td>
<td>Remove</td>
<td>Removed blue note box below question 1: If your center considers this to be a Donor Lymphocyte Infusions (DLI), as reported on the Pre-CTED (4000) form, product name will not be auto-populated. Select Other product for the product name.</td>
<td>DLIs are no longer reported on the F4100.</td>
</tr>
</tbody>
</table>

Last modified: Sep 23, 2022
Question 2: Date of actual contact with the recipient to determine medical status for this follow-up report:

Enter the date of actual contact with the recipient to evaluate medical status for this follow up report.

In general, the date of contact closest to the designated time point indicated on the form (e.g., Day+100, 6 months, or annual follow-up visit) should be reported. Report the date of actual contact with the recipient to evaluate medical status for the reporting period. Preferred evaluations include those from the cellular therapy physician, referring physician, or other physician currently assuming responsibility for the recipient’s care. In the absence of contact with a physician, other types of contact may include a documented phone call with the recipient, a laboratory evaluation, or any other documented recipient interaction on the date reported. If there was no contact on the exact time point, choose the date of contact closest to the designated time point.

The guidelines below show an ideal approximate range for reporting each post-cellular therapy time point:

<table>
<thead>
<tr>
<th>Form</th>
<th>Time Point</th>
<th>Approximate Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>F4100</td>
<td>100 Days</td>
<td>+/- 15 days (Day 85–115)</td>
</tr>
<tr>
<td>F4100</td>
<td>6 Months</td>
<td>+/- 30 days (Day 150–210)</td>
</tr>
<tr>
<td>F4100</td>
<td>1 Year</td>
<td>+ 60 days (Day 365–425)</td>
</tr>
<tr>
<td>F4100</td>
<td>Annual reporting 2+ Years</td>
<td>+/- 30 days (Months 23-25, 35-37, etc.)</td>
</tr>
</tbody>
</table>

Recipients are not always seen within the approximate ranges and some discretion is required when determining the date of contact to report. In that case, report the date closest to the date of contact within reason. The examples below assume that efforts were undertaken to retrieve outside medical records from the primary care provider, but source documentation was not available.

**Example 1.** *The 100 day date of contact doesn’t fall within the ideal approximate range.*

The recipient had an infusion on 1/1/18 and is seen regularly until 3/1/18. After that, the recipient was referred home and not seen again until 7/1/18 for a restaging exam and 7/5/18 for a meeting to discuss the results.

What to report:
100 Day Date of Contact: 3/1/18 (Since there was no contact closer to the ideal date of 4/11/18, this date...
is acceptable)
6 Month Date of Contact: 7/5/18 (note the latest disease assessment would likely be reported as 7/1/18)

**Example 2.** *The 100 day date of contact doesn’t fall within the ideal approximate range and the recipient wasn’t seen again until 1 year post-cellular therapy.*

The recipient had an infusion on 1/1/18 and is seen regularly until 3/1/18. After that, the recipient was referred home and not seen again until 1/1/19 for a restaging exam and 1/4/19 for a meeting to discuss the results.

What to report:
100 Day Date of Contact: 3/1/18 (Since there was no contact closer to the ideal date of 4/11/18, this date is acceptable)
6 Month form: Indicate the recipient is lost to follow-up in FormsNet3
1 Year Date of Contact: 1/4/19 (note the latest disease assessment would likely be reported as 1/1/19)

**Additional information:**

A date of contact should never be used multiple times for the same recipient’s forms.

- For example, 6/1/18 should not be reported for both the 6 month and 1 year. Instead, determine the best possible date of contact for each reporting period; if there is not a suitable date of contact for a reporting period, this may indicate that the recipient was lost to follow-up.

If the recipient has a disease evaluation just after the ideal date of contact, capturing that data on the form may be beneficial.

- For example, if the recipient’s 90 day restaging exam was delayed until day 115 and the physician had contact with the recipient on day 117, the restaging exams can be reported as the latest disease assessment and day 117 would be the ideal date of contact, even though it is just slightly after the ideal approximate range for the date of contact.

**Date of Contact & Subsequent Infusion**

If the recipient has a subsequent infusion, report the date of contact as the day before the preparative regimen / systemic therapy begins for the subsequent infusion. If no preparative regimen / systemic therapy is given, report the date of contact as the day before the subsequent infusion. In these cases, actual contact on that day is **not** required, and the day prior to the initiation of the preparative regimen / systemic therapy (or infusion, if no preparative regimen / systemic therapy was given) should be reported. This allows every day to be covered by a reporting period and prevents overlap between infusion events.

**Example 3.** *The recipient receives a subsequent HCT.*

The recipient had a cellular therapy on 1/1/18 and was seen regularly through the first 100 days. During the 6-month reporting period, the recipient goes on to receive a subsequent HCT.
What to report:

1. **Regulatory requirements specify at least 15 years of follow-up data be collected on recipients of genetically modified cellular therapy products:** The date of contact reported should be the date prior to the start of the preparative regimen (or infusion, if no preparative regimen was given). Both HCT and cellular therapy forms will be completed simultaneously, but all applicable cellular therapy follow-up forms will be reset to the new event date (i.e., Forms 2450+4100 or Forms 2100+4100). The forms will then have the same event date and due date.

2. **Cellular therapy products where regulatory requirements do not specify follow-up reporting:** The date of contact reported should be the date prior to the start of the preparative regimen (or infusion, if no preparative regimen was given). **Reporting on the cellular therapy event will end.**

**Combined follow up**
In scenarios where both HCT and cellular therapy forms are being completed, the contact date must match between the Form 2100+4100 or Form 2450+4100.

**Example 4.** *The recipient receives a subsequent cellular therapy.*
The recipient had a cellular therapy on 2/12/18 and was seen regularly through the first 100 days. During the 6-month reporting period, the recipient goes on to receive a subsequent cellular therapy.

**What to report**
The date of contact reported will be the date prior to the start of the systemic therapy (e.g., lymphodepleting therapy) for the subsequent infusion (in cases where no systemic therapy is given, it is the day prior to the infusion). **Reporting on the first cellular therapy event will end.** This is true for both genetically modified and non-genetically modified cellular therapy products.

**Date of Contact & Death**
In the case of recipient death, the date of death should be reported as the date of contact regardless of the time until the ideal date of contact. The date of death should be reported no matter where the death took place (inpatient at the transplant facility, at an outside hospital, in a hospice setting, or within the recipient’s home).

If the death occurred at an outside location and records of death are not available, the dictated date of death within a physician note may be reported. If the progress notes detailing the circumstances of death are available, request these records. These records are useful for completing required follow-up data fields and the cause of death data fields on this form. If the exact date of death is unknown, please view [General Instructions, General Guidelines for Completing Forms](#) for more information on reporting partial and unknown dates.

**Example 5.** *The recipient has died before their six month reporting period.*
The recipient had an infusion on 1/1/18 and was seen regularly through the first 100 days. They had restaging exams on 4/4/18 and were seen on 4/8/18, and then died on 5/13/18 in the hospital emergency room.

**What to report:**
Example 6. *The recipient has died after their six month time point.*

The recipient had an infusion on 1/1/18 and was seen regularly through the first 100 days. The recipient had restaging exams on 4/22/18 and was seen on 4/23/18. Based on findings in the restaging exam, the recipient was admitted for additional treatment. The disease was found to be refractory on a 6/25/18 restaging exam, and the recipient was discharged to hospice on 7/8/18. The hospital was notified via telephone that the recipient died on 7/16/18.

What to report:
100 Day Date of Contact: 4/23/18 (note the latest disease assessment would likely be reported as 4/22/18)
6 Month Date of Contact: 7/16/18 (note the latest disease assessment would likely be reported as 6/25/18)

**Question 3: Specify the recipient’s survival status at the date of last contact:**

Indicate the clinical status of the recipient on the date of actual contact for follow-up evaluation. If the recipient has died, answers to subsequent questions should reflect the recipient’s clinical status between the date of last report and their death. The center must also complete a Recipient Death Data (2900) form.

**Combined follow up**

In scenarios where both HCT and cellular therapy forms are being completed, the death must be reported on both the HCT and cellular therapy forms. If there are Comprehensive Report forms for the HCT, two Recipient Death Data (2900) forms will come due. You only need to complete one form. Contact CIBMTR Center Support to remove the duplicate.

**Question 4: Was the recipient admitted to the hospital post-infusion?**

The practice of outpatient cellular therapy infusions is increasing however there might still be the need for admission for cellular therapy toxicities. In order to capture if patients require admission following cellular therapy a date of admission and discharge will be collected in Questions 5-6.

**Question 5: Date of first hospital admission:**

Report the first date (YYYY-MM-DD) the recipient was admitted to the hospital post-infusion.

For more information regarding reporting partial or unknown dates, see [General Instructions, General Guidelines for Completing Forms](#).
**Question 6: Date of first discharge:**

Report the date (YYYY-MM-DD) of first discharge after the first hospital admission.

For more information regarding reporting partial or unknown dates, see [General Instructions, General Guidelines for Completing Forms](#).

### Section Updates:

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2</td>
<td>2/15/2023</td>
<td>Add</td>
<td>The ‘No Documentation of Contact Date’ red warning box added: <strong>No Documentation of Contact Date</strong> The contact date data field cannot be left blank and is required to be reported. In cases where the recipient passed away and there is no documentation to report the date of death, the guidelines for reporting estimated dates must be used.</td>
<td>Added for clarification</td>
</tr>
</tbody>
</table>

Last modified: Feb 15, 2023
Q7-12: Subsequent Cellular Infusions

Combined follow up
In scenarios where both HCT and cellular therapy forms are being completed, duplicate questions will exist between the Cellular Therapy Essential Data Follow-Up (4100) form and the Post-HCT Data (2100) or Post-Transplant Essential Data (2450) form. To reduce the reporting burden, duplicate questions, including subsequent infusions, on the Cellular Therapy Essential Data (4100) form are disabled and will be answered on the Post-HCT Data (2100) or Post-Transplant Essential Data (2450) form.

Subsequent Cellular Infusions
All additional cellular therapy infusions of the same product given for the same indication per protocol require a separate Cellular Therapy Infusion (4006) form. However, they will only require a single Cellular Therapy Product (4003) form for this course of cellular therapy. If a cellular therapy was administered for a different indication (i.e., in response to disease progression / no response, another infusion of a commercial product, etc.) a new Pre-Cellular Therapy Essential Data (4000) form must be completed.

Question 7: Has the recipient received a new course of cellular therapy (unplanned) since the date of the last report?

Cellular Therapy Infusions Over Multiple Reporting Periods
If a course of cellular therapy carries over a reporting period, and has already been reported on a prior form, do not re-report that course of cellular therapy. For example, if a course of cellular therapy includes three infusions, and the third infusion overlaps from the one year to two-year reporting period, do not report a new cellular therapy since the date of the last report on the two year follow up form. This would trigger a new Pre-CTED (4000) form which is not required for infusions part of a single course of cellular therapy.

A course of cellular therapy consists of all infusions given for the same indication per protocol. If the recipient started a new course of cellular therapy (unplanned) that is different than the course this follow up form is being completed for, select Yes.

If additional infusions were given for the same indication per protocol, do not report those infusions here. Update the Cellular Therapy Product (4003) form for the applicable product with the correct number of infusions given per protocol. Each infusion requires a separate Cellular Therapy Infusion (4006) form.

In cases where a new course of cellular therapy is being given post-HCT, only the first infusion is reported on the appropriate HCT follow up form (either the Post-HCT Data (2100) or Post-Transplant Essential Data (2450) form). Remaining infusions of a single course of cellular therapy (e.g., multiple DCI/DLIs) are not reported as subsequent infusions. They are captured on a single Cellular Therapy Product (4003) Form as the number of planned infusions.

Example 1. The new course of cellular therapy (post-HCT) consisting of multiple infusions started at the
end of the 6-month HCT reporting period and continued into the beginning of the 1-year HCT reporting period.

**How to report:** The new course of cellular therapy should be reported only on the 6-month HCT follow-up form (either the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450) form) and not on the Cellular Therapy Essential Data Follow-Up (4100) form.

- Reporting an infusion on the Cellular Therapy Essential Data Follow-Up (4100) form as a subsequent infusion will generate a new Pre-Cellular Therapy Essential Data (4000) form. If you need help removing a Pre-Cellular Therapy Essential Data (4000) form, please make sure the field is corrected and contact CIBMTR Center Support to remove the form.

**Example 2.** Two non-genetically modified courses of post-HCT cell therapy (e.g., DCI/DLI and MSCs) are given within 100 days of each other in the same reporting period.

**How to report:** Report the first course as a subsequent cellular therapy on either the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450) form. This will make a new Pre-Cellular Therapy Essential Data (4000) form due. When it is completed, report the second course of cellular therapy on the 100-day Cellular Therapy Essential Data Follow-Up (4100) form to generate the second Pre-Cellular Therapy Essential Data (4000) form.

**Example 3.** Two non-genetically modified courses of post-HCT (e.g., DCI/DLI and MSCs) are given greater than 100 days apart, but still within the same reporting period.

**How to report:** Report the first course as a subsequent cellular therapy on the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450) form. Then create a new indication form to report the second course, which will make a second Pre-Cellular Therapy Essential Data (4000) form come due.

**Example 4.** Two genetically modified courses of post-HCT (e.g., Kymriah® and Yescarta®) are given in the same reporting period.

**How to report:** Report the first course as a subsequent cellular therapy on the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450) form. This will make a new Pre-Cellular Therapy Essential Data (4000) form due. When it is completed, combined follow up rules will apply and both HCT and cellular therapy forms will be completed. Report the second course of cellular therapy on the 100-day Cellular Therapy Essential Data Follow-Up (4100) form to generate the second Pre-Cellular Therapy Essential Data (4000) form.

**Question 8: Was this infusion a Donor Lymphocyte Infusion?**

Donor lymphocyte infusions (DLI) are considered a type of cellular therapy. These infusions are not intended to promote hematopoiesis. If the recipient received additional cells due to engraftment issues, or if they received an infusion of unmanipulated CD34+ cellular product (stimulated peripheral blood stem cells, bone marrow, or cord blood), report as a subsequent HCT rather than a cellular therapy. For more information on how to distinguish infusion types (example: HCT versus DCI), see **Appendix D**.
Indicate if the infusion was a donor lymphocyte infusion (DLI). An infusion is donor lymphocyte infusion when all the following criteria are met:

- The intent of the infusion is something other than to restore hematopoiesis
- The infusion must be post-Allogenic HCT, often by the same donor as the HCT
- The product must be a lymphocyte-only product
- The product cannot be genetically modified

If the infusion meets the above definition of DLI, select Yes and complete the Donor Lymphocyte Infusion (2199) form instead of the Cellular Therapy Essential Data Pre-Infusion (4000) form.

If the infusion does not meet DLI criteria, select No.

**Question 9: Specify the reason for which cellular therapy was given:**

If the reason for the new course of cellular therapy was Failure to respond or in response to disease assessment or for a New indication, continue with question 10 to report the event date.

**Question 10: Date of cellular therapy:**

Report the date (YYYY-MM-DD) of the new course of cellular therapy (unplanned). If the new course of cellular therapy includes multiple infusions, the date of the first infusion should be reported here. This will require completion of a new Pre-Cellular Therapy Essential Data (4000) form.

**Questions 11 – 12: Did the recipient receive an HCT since the date of last report?**

If the recipient received an HCT since the date of the last report, select Yes and report the date (YYYY-MM-DD) of the HCT in question 8; also complete the Pre-Transplant Essential Data (2400) form.

**Combined follow up**

Regulatory requirements specify at least 15 years of follow-up data be collected on recipients of genetically modified cellular therapy products, reporting on the cellular therapy event will continue. Both HCT and cellular therapy forms will be completed.

If the recipient did not receive an HCT since the date of the last report, report No and continue with question 13.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/ Remove/ Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>10/17/2022</td>
<td>Modify</td>
<td>Updated the continue with question number: If the reason for the new course of cellular therapy was Failure to respond or in response to disease assessment or for a New indication, The question number</td>
<td></td>
</tr>
<tr>
<td>Question</td>
<td>Date</td>
<td>Type</td>
<td>Change</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>------</td>
<td>------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>7/29/2021</td>
<td>Add</td>
<td>Added new blue note box below question 7: <strong>Cellular Therapy Infusions Over Multiple Reporting Periods:</strong> If a course of cellular therapy carries over a reporting period, and has already been reported on a prior form, do not re-report that course of cellular therapy. For example, if a course of cellular therapy includes three infusions, and the third infusion overlaps from the one year to two-year reporting period, do not report a new cellular therapy since the date of the last report on the two year follow up form. This would trigger a new Pre-CTED (4000) form which is not required for infusions part of a single course of cellular therapy.</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>7/29/2021</td>
<td>Modify</td>
<td>Removed the reference to DLI in Example 2 &amp; Example 3: Two non-genetically modified courses of post-HCT cell therapy (e.g., DCI/DLI and MSCs)</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>7/29/2021</td>
<td>Modify</td>
<td>Updated the question description and definition of DLI</td>
<td></td>
</tr>
</tbody>
</table>

Last modified: Oct 17, 2022
Q13-15: Best Response to Cellular Therapy

This section may not fit perfectly to all possible indications for cellular therapy. Please select the response that is most applicable to the indication for treatment.

If the primary disease reported is Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL), or Multiple Myeloma (MM) best response is not reported on this form. It will be captured on the corresponding disease form. The question should be left blank and override the error with the override code “Verified Correct (VC)” at this time.

If the indication for this course of cellular therapy does not require the completion of disease-specific forms, please refer to the disease-specific manuals to locate the response criteria that should be used when reporting best response.

Question 13: What was the best response to the cellular therapy?

This section collects the data known as “best response to cellular therapy”. The purpose of this section is to report the recipient’s best response to the planned course of cellular therapy. This section applies to both malignant and non-malignant diseases and disorders. If the recipient received a prior HCT, do not report the response to the HCT, a separate evaluation to establish best response after the cellular therapy is required.

Combined follow up

If the recipient receives a subsequent HCT, do not report the best response to the HCT here. The reported best response to the cellular therapy was previously reported and can no longer be evaluated once a recipient has a subsequent HCT. Continue to report best response achieved from the cellular therapy.

For malignant diseases (including solid tumors), appropriate responses are:

- Continued complete response
- Complete response
- Partial response
- No response
- Disease progression

For non-malignant disorders and cardiovascular, musculoskeletal, neurologic, ocular or pulmonary disease, appropriate responses are:

- Normalization of organ function
- Partial normalization of organ function
- No response
• Worsening of organ function

If the indication is infection, the appropriate responses are:

• Complete response
• Partial response
• No response

Table 1. Examples of best response to cellular therapy.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Applicable response options</th>
<th>Partial Response</th>
<th>Complete Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>GVHD prophylaxis (with HCT)</td>
<td>Do not answer best response</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Prevent disease relapse</td>
<td>Do not answer best response</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Infection prophylaxis</td>
<td>Do not answer best response</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Suboptimal donor chimerism (post-HCT)</td>
<td>Complete Response, Partial Response, or No Response</td>
<td>Increase in chimerism but not 100% donor</td>
<td>100% donor chimerism</td>
</tr>
<tr>
<td>Immune Reconstitution (post-HCT)</td>
<td>Complete Response or No Response</td>
<td>-</td>
<td>CD3 &gt;200/mm³</td>
</tr>
<tr>
<td>GVHD treatment (post-HCT)</td>
<td>Complete Response, Partial Response, or No Response</td>
<td>Improvement but not resolution of symptoms, Remains on immune suppression</td>
<td>Improvement but not resolution of symptoms, or Remains on immune suppression</td>
</tr>
<tr>
<td>Malignant Hematologic Disorder</td>
<td>Complete Response, Partial Response, Progression, or No Response</td>
<td>Refer to the response criteria as published in the disease specific manual</td>
<td>Refer to the response criteria as published in the disease specific manual</td>
</tr>
<tr>
<td>Non-Malignant Disorder</td>
<td>Normalization of organ function, Partial normalization of organ function, No response, Worsening of organ function</td>
<td>Persistent Disease</td>
<td>Resolution of Disease Process</td>
</tr>
<tr>
<td>Solid Tumor</td>
<td>Complete Response, Partial Response, No Response, or Disease Progression</td>
<td>Improvement in disease burden, but with persistent disease</td>
<td>No evidence of disease</td>
</tr>
<tr>
<td>Cardiovascular Disease, Musculoskeletal Disorder</td>
<td>Do not answer best response</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Neurologic Disease, Ocular Disease, Pulmonary Disease

<table>
<thead>
<tr>
<th>Infection treatment</th>
<th>Complete Response, Partial Response, No Response, or Unknown</th>
<th>Decrease in infectious burden without resolution</th>
<th>Undetectable infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other</td>
<td>Do not answer best response</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

If the recipient relapses / progresses post-infusion and receives therapy for the disease relapse / progression, the response to that additional therapy should not be reported in this section. The best response prior to the relapse/ progression should be reported.

**Question 14-15: Was the date of best response previously reported?**

If the date of best response was previously reported, select *Yes* and continue with question 16. **This option is not applicable on the 100 day report.**

**Combined follow up**

If the recipient receives an HCT after a cellular therapy and the best response to the cellular therapy was previously reported, it can no longer be evaluated once a recipient has a subsequent HCT. It is appropriate to report *Yes* for this scenario on the 100 day report.

If the date of best response has not been reported, select *No* and report the date (YYYY-MM-DD) in question 15. The date of best response should be the first date all criteria were met.

If the exact date is unknown, please view [General Instructions, General Guidelines for Completing Forms](https://www.cibmtr.org) for more information on reporting partial and unknown dates.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13-15</td>
<td>2/20/23</td>
<td>Modify</td>
<td>Updated the applicable response options for non-malignant disease in Table 1: Complete Response, Partial Response, or No Response Normalization of organ function, Partial normalization of organ function, No response, Worsening of organ function</td>
<td>The values were incorrect.</td>
</tr>
</tbody>
</table>

Last modified: Feb 20, 2023
Q16-24: Peripheral Blood Count Recovery

Combined follow up
In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, these questions do not apply and are disabled.

Example 1. Cellular therapy after HCT: completion of this form should be based on the time period in relation to the CT infusion date (i.e., 100 days after the CT infusion date). The visit ID should match between the corresponding Post-HSCT Data (2100) or Post-Transplant Essential Data (2450).

Example 2. HCT after cellular therapy: These questions do not apply and are disabled.

The reporting of peripheral blood count recoveries on the Cellular Therapy Essential Data Follow-Up (4100) form has a different intent than the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450). Systemic therapy (such as lymphodepleting therapy given prior to a CAR-T infusion) may negatively impact ANC and platelet counts. The intent of the questions on the Cellular Therapy Essential Data Follow-Up (4100) form is to determine cell count recovery post systemic therapy, not as a measure of engraftment. These questions are not applicable to all cellular therapies. Not all types of cellular therapies require a course of systemic therapy prior to the infusion.

Absolute neutrophil recovery (ANC) recovery is defined as an ANC of ≥ 500/mm³ (or ≥ 0.5 × 10⁹/L) for three consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of three consecutive laboratory values where the ANC is ≥ 500/mm³. At some institutions, the laboratory reports display the ANC value once there are sufficient white blood cells to perform a differential count. At other institutions, the laboratory reports do not display the ANC, and it must be calculated from the white blood cell count (WBC). The percent neutrophils (if the differential was performed on an instrument, will include both segmented and band neutrophils. If the laboratory report displays an automated ANC value of exactly 500/mm³, the actual ANC value should be calculated from the manual differential if available. The calculated value from the manual differential will determine ANC recovery. If your institution’s laboratory reports do not display the ANC value, use the following calculation to determine the ANC:

Example 3: Calculating Absolute Neutrophil Count (ANC)
Traditionally, the definition of ANC recovery required the selection of the first date of three consecutive days in which the recipient’s ANC was ≥ 0.5×10^9/L (500/mm^3). For various reasons it may not be possible to obtain daily laboratory values. Under those circumstances, report ANC recovery based upon three consecutive laboratory values (drawn more than a day apart) as long as the ANC remains ≥ 0.5×10^9/L (500/mm^3).

Tracking the date of ANC recovery may not always be straightforward. In some cases, the ANC may fluctuate for a period of time before the recipient fully recovers. In other cases, the ANC may remain above ≥ 500/mm^3 for several days immediately post-HCT and then fall below ≥ 500/mm^3. Do not begin counting ANC values of ≥ 500/mm^3 towards recovery until the ANC has dropped to the lowest level (nadir) post-infusion. See the following example for more information regarding tracking the date of ANC recovery.

To report dates in this question, use the first of 3 consecutive laboratory values obtained on different days.

**Example 4:** Tracking ANC Recovery

Infusion Date = May 6  
Contact Date = August 15

<table>
<thead>
<tr>
<th>Date</th>
<th>WBC</th>
<th>%Neutrophils</th>
<th>ANC</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 7</td>
<td>900</td>
<td>0.6</td>
<td>540</td>
</tr>
<tr>
<td>May 8</td>
<td>850</td>
<td>0.59</td>
<td>502</td>
</tr>
<tr>
<td>May 9</td>
<td>720</td>
<td>0.7</td>
<td>504</td>
</tr>
<tr>
<td>May 10</td>
<td>300</td>
<td>0.45</td>
<td>135</td>
</tr>
<tr>
<td>Date</td>
<td>WBC</td>
<td>%Neutrophils</td>
<td>ANC</td>
</tr>
<tr>
<td>---------------</td>
<td>------</td>
<td>--------------</td>
<td>------</td>
</tr>
<tr>
<td>May 7</td>
<td>900</td>
<td>0.6</td>
<td>540</td>
</tr>
<tr>
<td>May 8</td>
<td>850</td>
<td>0.59</td>
<td>502</td>
</tr>
<tr>
<td>May 9</td>
<td>720</td>
<td>0.7</td>
<td>504</td>
</tr>
<tr>
<td>May 10</td>
<td>300</td>
<td>0.45</td>
<td>135</td>
</tr>
<tr>
<td>May 11</td>
<td>15</td>
<td>No differential</td>
<td>—</td>
</tr>
<tr>
<td>May 12</td>
<td>30</td>
<td>No differential</td>
<td>—</td>
</tr>
<tr>
<td>May 13</td>
<td>50</td>
<td>No differential</td>
<td>—</td>
</tr>
<tr>
<td>May 14</td>
<td>250</td>
<td>0.4</td>
<td>100</td>
</tr>
<tr>
<td>May 15</td>
<td>800</td>
<td>0.7</td>
<td>560</td>
</tr>
</tbody>
</table>

*Example 5: Initial Recovery with Subsequent Decline and Recovery*

Transplant Date = May 6
Contact Date = August 15

Date of initial recovery: ANC ≥ 500/mm³ (report this date in question 13)
<table>
<thead>
<tr>
<th>Date</th>
<th>ANC</th>
<th>WBC</th>
<th>Date of first decline: ANC ≤ 500/mm³ (report this date in question 15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 17</td>
<td>1000</td>
<td>0.7</td>
<td>700</td>
</tr>
<tr>
<td>May 18</td>
<td>1800</td>
<td>0.6</td>
<td>1080</td>
</tr>
<tr>
<td>May 19</td>
<td>2000</td>
<td>0.55</td>
<td>1100</td>
</tr>
<tr>
<td>May 20</td>
<td>2500</td>
<td>0.53</td>
<td>1325</td>
</tr>
<tr>
<td>May 21</td>
<td>2250</td>
<td>0.43</td>
<td>968</td>
</tr>
<tr>
<td>May 22</td>
<td>1500</td>
<td>0.45</td>
<td>675</td>
</tr>
<tr>
<td>May 23</td>
<td>800</td>
<td>0.6</td>
<td>480</td>
</tr>
<tr>
<td>May 24</td>
<td>850</td>
<td>0.41</td>
<td>349</td>
</tr>
<tr>
<td>May 25</td>
<td>720</td>
<td>0.53</td>
<td>382</td>
</tr>
<tr>
<td>May 26</td>
<td>500</td>
<td>0.45</td>
<td>225</td>
</tr>
<tr>
<td>May 27</td>
<td>490</td>
<td>0.3</td>
<td>147</td>
</tr>
<tr>
<td>May 28</td>
<td>650</td>
<td>0.7</td>
<td>455</td>
</tr>
<tr>
<td>May 29</td>
<td>800</td>
<td>0.8</td>
<td>640</td>
</tr>
<tr>
<td>May 30-August 14</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>August 15 (contact date)</td>
<td>2245</td>
<td>0.72</td>
<td>1616</td>
</tr>
</tbody>
</table>

**Question 16: Was there evidence of initial recovery?**

This question is not applicable to all cellular therapies. Some cellular therapies require a course of systemic therapy prior to the infusion, such as in the case of chimeric antigen receptor (CAR) T-cells. One of the described toxicities is the inability for hematologic recovery, either by an added cycle of chemotherapy in a recipient who received many prior lines of chemotherapy or by a direct toxicity from the cellular therapy.

Indicate whether or not there was evidence of initial ANC recovery following this infusion.

Check only one response:

- If **Yes**, continue with question 17
- If **No**, continue with question 23
- Report **Not applicable**, if the recipient’s ANC never dropped below 500/mm³ (or ≥ 0.5 × 10⁹/L) at any time post- cellular therapy infusion or the recipient did not receive lymphodepleting therapy. This option is only applicable in the 100 day reporting period. Continue with question 23.
• Report Previously reported if this is the 6 month or annual follow-up, and ANC initial recovery (including Not applicable) has already been reported on a previous form. Continue with question 23.

Combined follow up
If the recipient receives an HCT after a cellular therapy, and both HCT and cellular therapy forms are being completed, select Previously reported on all Cellular Therapy Essential Data Follow-Up (4100) forms. Peripheral blood count recoveries will now be captured in the context of engraftment on the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450).

Question 17: Date ANC >500/mm³ (first of 3 lab values):
Enter the first date of the three consecutive laboratory values obtained on different days where the ANC was ≥ 500/mm³ (or ≥ 0.5 × 10⁹/L). For an example of tracking ANC, see Example 4 above.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Question 18: Following the initial recovery, was there subsequent decline in ANC to < 500/mm³ for ≥ 3 days since the date of last report?

Report if there was subsequent decline in ANC < 500/mm³ (or < 0.5 × 10⁹/L) (three consecutive laboratory values obtained on different days where the ANC declined to < 500/mm³. If Yes continue with question 19. If No continue with question 23.

Multiple Recoveries and Declines
The form does not allow for multiple recoveries and declines in the same reporting period. If the recipient’s ANC initially recovers and then declines, followed by another recovery and another decline, report the date of the first (initial) recovery (question 19), the first decline (question 19), and the last recovery (question 22).

Question 19: Date of decline in ANC to < 500/mm³ for ≥ 3 days (first of 3 days that the ANC declined):
Enter the first date of the three consecutive laboratory values obtained on different days where the ANC declined to < 500/mm³ (or < 0.5 × 10⁹/L). For an example of tracking a subsequent decline and recovery, see Example 5 above.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.
**Question 20: Did recipient recover and maintain ANC ≥ 500/mm3 following the decline?**

Indicate whether there was evidence of ANC recovery following the decline (three consecutive laboratory values obtained on different days where the ANC was ≥ 500/mm3 (or ≥ 0.5 × 10⁹/L). If Yes, continue with question 21. If No, continue with question 23.

**Questions 21 – 22: Date of ANC recovery**

Report if the date of ANC recovery following the decline is Known or Unknown. If the date of recovery is Known, enter the first date of the three consecutive laboratory values obtained on different days where the ANC recovered to ≥ 500/mm³ (or ≥ 0.5 × 10⁹/L) following the decline. For an example of tracking a subsequent decline and recovery, see Example 5 above. If the date of recovery following decline is Unknown, continue with question 23.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

**Question 23: Was an initial platelet count > 20 × 10⁹/L achieved?**

This question does not apply to all cellular therapies. Some cellular therapies require a course of systemic therapy prior to the infusion, such as in the case of chimeric antigen receptor (CAR) T-cells. One of the described toxicities is the inability for hematologic recovery, either by an added cycle of chemotherapy in a recipient who received many prior lines of chemotherapy or by a direct toxicity from the cellular therapy.

The following questions refer to initial platelet recovery following the cellular therapy infusion for which this form is being completed. All dates should reflect no platelet transfusions administered in the previous seven days. Report the date of the first of three consecutive laboratory values ≥ 20 × 10⁹/L obtained on different days, as shown in Example 6 below. Note that platelet recovery may take place well after the recipient has returned to the referring physician for care. It is essential that information and laboratory values be obtained from the referring physician.

Transfusions temporarily increase platelet counts. When the data is later used for analysis, it is important to be able to distinguish between a recipient whose body was creating the platelets on its own and a recipient who required transfusions to support the counts.

The following example illustrates the procedure to follow for reporting platelet recovery.

**Example 6. Reporting Platelet Recovery**
This question relates to initial platelet recovery. Dates should not reflect transfusions that took place 7 days prior to the date that it listed. To report dates in this question, use the first of 3 consecutive laboratory values obtained on different days.

Indicate whether or not there was evidence of initial platelet recovery following this cellular therapy infusion. Check only one response:

- If Yes, continue with question 24.
- If No, continue with question 25.
- Report Not applicable, if the recipient’s platelets never dropped below 20 × 10^9/L at any time post-cellular therapy infusion and a platelet transfusion was never required at time post-cellular therapy infusion or the recipient did not receive lymphodepleting therapy. If the recipient’s platelet count drops below 20 × 10^9/L and/or the recipient received a platelet transfusion even once, do not report Not applicable. This option is only applicable in the 100-day reporting period. Continue with question 25.

- Report Previously reported if this is the 6 month or annual follow-up, and initial platelet recovery (including Not applicable) has already been reported on a previous form. Continue with question 25.

**Combined follow up**

If the recipient receives an HCT after a cellular therapy, and both HCT and cellular therapy forms are being completed, select Previously reported on all Cellular Therapy Essential Data Follow-Up (4100) forms. Peripheral blood count recoveries will now be captured in the context of engraftment on the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450).

**Question 24: Date platelets > 20 × 10^9/L:**

Enter the first date of three consecutive laboratory values obtained on different days where the platelet count was ≥ 20 × 10^9/L. Ensure that no platelet transfusions were administered for seven days immediately preceding this date. Include day seven, as shown in Example 6 above, when determining the recovery date. If three laboratory values were not obtained on consecutive days, but a sequential rise of ≥ 20 × 10^9/L is demonstrated, follow the examples below when determining an estimated date.
Reporting Scenarios:

A. The recipient is being seen in the outpatient clinic and receives a platelet transfusion on January 1. The platelet count is $22 \times 10^9/L$ on January 2, $24 \times 10^9/L$ on January 3, and $28 \times 10^9/L$ on January 4. The recipient does not come into the clinic for evaluation until one month later. The recipient has not received any more platelet transfusions and the platelet count is well above $20 \times 10^9/L$. Report January 8 (day seven post-platelet transfusion) for the date of platelet recovery.

B. The recipient is being seen in the outpatient clinic and receives a platelet transfusion on January 1. The platelet count is $\geq 20 \times 10^9/L$ on January 2, January 3, and January 4. The recipient is then discharged back to their primary care physician. The transplant center receives a follow-up note from the primary care physician that states “recipient recovered their platelets in January of 2011.” Report an estimated date of recovery using the guidelines available in General Instructions, General Guidelines for Completing Forms.

Section Updates:

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/RemoveModify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>7/29/2021</td>
<td>Modify</td>
<td>Updated example 2 of Combined follow up: Example 2. HCT after cellular therapy: These questions do not apply and are disabled.</td>
<td>The validations were updated to disable these questions.</td>
</tr>
<tr>
<td>16</td>
<td>7/29/2021</td>
<td>Modify</td>
<td>Removed the reference to DLI in blue note box below question 16: Report Not applicable for DCI/DLI infusions where systemic therapy was not given pre-infusion.</td>
<td>DLIs are no longer reported on the F4100.</td>
</tr>
<tr>
<td>23</td>
<td>7/29/2021</td>
<td>Modify</td>
<td>Removed the reference to DLI in blue note box below question 23: Report Not applicable for DCI/DLI infusions where systemic therapy was not given pre-infusion.</td>
<td>DLIs are no longer reported on the F4100.</td>
</tr>
</tbody>
</table>
Q25-31: Disease Relapse or Progression

Question 25-26: Was a disease relapse or progression detected since the date of last report?

Disease relapse or progression can be documented by a variety of methods including molecular, flow cytometry, cytogenetic/fluorescent in situ hybridization (FISH), radiographic or hematological/clinical. Report Yes if disease relapse or progression was detected by any one of the methods in the current reporting period and report the first date (YYYY-MM-DD) of the relapse or progression detected.

If a disease relapse or progression was not detected in the current reporting period, report No and continue with question 27.

Question 27: Was there evidence of antigen escape?

Many cellular therapies are designed to target a specific tumor antigen(s). One mechanism of resistance to these cellular therapies includes antigen escape. This is when the tumor develops partial or complete loss of the tumor antigen. An example is a recipient with acute lymphoblastic leukemia (ALL) that expresses the CD19 antigen prior to cellular therapy infusion. The patient is given a CD19-directed CAR T-cell therapy and at the time of relapse their leukemia cells no longer express CD19. This may be determined by testing on the blood and/or bone marrow showing absence of the tumor antigen targeted by the cellular therapy they received.

Report Yes if there was evidence of antigen escapes and continue with question 28.

If there was no evidence of antigen escapes in the current reporting period, report No and continue with question 32.

Question 28 – 29: Method of detection of antigen escape (check all that apply)

Methods of detecting antigen escape include Flow cytometry, Immunohistochemistry (IHC) or Other method. Select the method(s) used to detect antigen escape. If Other method is selected, specify what method was used in question 29.

Question 30: Was documentation submitted to CIBMTR?

Indicate whether documentation of the antigen escape was submitted to CIBMTR (e.g., pathology report, autopsy report). For further instructions on how to attach documents in FormsNet3SM, refer to the Formsnet3 Training Guide.
**Question 31: Date of antigen escape**

Report the date (YYYY – MM- DD) when testing first showed evidence of antigen escape.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Last modified: Sep 23, 2022*
Q32-42: Current Hematologic Findings

**Question 32: Date of most recent complete blood count (CBC) sample drawn:**

These questions are intended to determine the clinical status of the recipient at time of follow-up for this reporting period post cellular therapy. Testing may be performed multiple times post-infusion; report the most recent CBC obtained.

**Questions 33-41: Complete blood count results available: (check all that apply)**

For each cell type listed, checking the box will indicate a result is available. Provide the most recent laboratory values from the CBC on the date reported in the prior question.

**WBC:** The white blood cell count is a value that represents all the white blood cells in the blood. If the count is too high or too low, the ability to fight infection may be impaired. Report the WBC value in question 34.

**Neutrophils:** Neutrophils are a subtype of white blood cell that fights infection. The value on the laboratory report may be a percentage or an absolute value. If an absolute value is reported, divide it by the white blood cell count for a percentage. Neutrophils are also known as polymorphonuclear leukocytes (PMNs). Report the neutrophil value in question 35.

**Lymphocytes:** Lymphocytes are another subtype of white blood cell that fights infection. The value on the laboratory report may be a percentage of an absolute value. If an absolute value is reported, divide it by the white blood cell count for a percentage. Report the lymphocyte value in question 36.

**Hemoglobin:** Hemoglobin is a molecule in red blood cells that delivers oxygen to tissues throughout the body. A low hemoglobin count is considered “anemia” and blood transfusions, or growth factors may be required to increase the hemoglobin level. Report the hemoglobin value in question 37.

**Hematocrit:** The hematocrit is the percentage (sometimes displayed as a proportion) of red blood cells relative to the total blood volume. A low hematocrit may require red blood cell transfusions or growth factors. Indicate if the recipient received a red blood cell transfusion within 30 days prior to sample draw date. Report the hematocrit value in question 38.

If a hematocrit value is reported, also indicate if the recipient received a red blood cell transfusion within 30 days prior to the date of the CBC reported in question 39.

**Platelets:** Platelets are formed elements within the blood that help with coagulation. A low platelet count, called thrombocytopenia, may lead to easy bleeding or bruising. Thrombocytopenia may require platelet transfusions. Indicate if the recipient received a platelet transfusion within 7 days prior to testing. Report the...
platelet value in question 40.

If a platelet value is reported, also indicate if the recipient received a platelet transfusion within 7 days prior to the date of the CBC reported in question 41.

**Questions 42: Did the recipient receive any growth factors <7 days before the date the sample was drawn?**

Indicate if the recipient received any growth factor (e.g., GCS-F) within 7 days prior to the date the CBC sample was drawn. In the event of a long acting growth factor (e.g., pegfilgrastim (Neulasta®)), please answer this question as **yes** if the recipient received it within 14 days prior to the date the CBC sample was drawn.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

_Last modified: Jan 28, 2022_
Q43: New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder

Combined follow up
If the recipient has received an HCT after a cellular therapy, and both HCT and cellular therapy forms are being completed, new malignancies will always be reported on the Cellular Therapy Essential Data Follow-Up (4100) forms and disabled on the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450).

Question 43: Did a new malignancy, myelodysplastic, myeloproliferative, or lymphoproliferative disease / disorder occur that is different from the disease / disorder for which the cellular therapy was performed? (Include clonal cytogenetic abnormalities, and post-transplant lymphoproliferative disorders):

Indicate Yes or No if a new or second primary malignancy, including lymphoproliferative disorder, or myeloproliferative disorder, developed in the current reporting period. Do not report recurrence, progression, or transformation of the recipient’s primary disease (disease for which the cellular therapy was performed) or relapse of a prior malignancy.

New malignancies, lymphoproliferative disorders, myelodysplastic and myeloproliferative disorders include but are not limited to:

- Skin cancers (basal, squamous, melanoma)
- New leukemia
- New myelodysplasia
- Solid tumors
- PTLD (post-transplant lymphoproliferative disorder) report as lymphoma or lymphoproliferative disease

The following should not be reported as new malignancy:

- Recurrence of primary disease (report as relapse or disease progression)
- Relapse of malignancy from recipient’s pre-cellular therapy medical history
- Breast cancer found in other (i.e., opposite) breast (report as relapse)
- Post-cellular therapy cytogenetic abnormalities associated with the pre-cellular therapy diagnosis (report as relapse)

If a new malignancy is reported, please complete the Subsequent Neoplasms (3500) form to answer questions specific to the new malignancy. The option of ‘Previously reported’ should only be used if the
same malignancy has already been reported on a Subsequent Neoplasms (3500) form that was made due
on demand. See examples below. If it is unclear whether or not to use of this option, contact CIBMTR
Center Support if there are questions.

**Example 1.** Recipient develops a new malignancy at day +68. It is reported at the time the 100-day Cellular
Therapy Essential Data Follow-Up (4100) form is completed. Question 43 should be answered as ‘yes’ and
the Subsequent Neoplasms (3500) form should be completed to report all new malignancy information.

**Example 2.** Recipient received a commercial CAR-T product and develops a new malignancy at day +68.
Per protocol, the new malignancy should be reported at the time of knowledge of the new malignancy. The
Subsequent Neoplasms (3500) form should be created as an unscheduled form in FormsNet3 and
completed in a timely manner. In this example, no other new malignancy develops during the 100-day
reporting period. When the 100-day Cellular Therapy Essential Data Follow-Up (4100) form is completed,
question 43 should be answered as ‘previously reported’.

**Example 3.** Recipient received a commercial CAR-T product and develops a new malignancy at day +68.
Per protocol, the new malignancy should be reported at the time of knowledge of the new malignancy. The
Subsequent Neoplasms (3500) form should be created as an unscheduled form in FormsNet3 and
completed in a timely manner. Another new malignancy develops at day +100 after the same CAR-T
infusion. It is decided to report the 2nd new malignancy on the 100-day Cellular Therapy Essential Data
Follow-Up (4100) form since it is due at the same time. Question 43 should be answered as ‘yes’ to create a
second Subsequent Neoplasms (3500) form.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

*Last modified: May 10, 2022*
Q44-68: Persistence of Cells

This section pertains to the evaluation of persistence of a cellular product in the recipient and only applies to genetically modified cellular therapy products.

Question 44: Were tests performed to detect persistence of the cellular product since the date of last report?

Methods such as PCR assays, flow cytometry (immunophenotyping) or immunohistochemistry can be used to detect direct persistence of the cellular product in the recipient.

It is possible to use other testing methods, such as monitoring B cells, as a surrogate for ongoing cellular therapy persistence. Surrogate testing should not be reported here. Monitoring of B cells can be reported in question 66.

If tests were performed to detect direct persistence of the cellular product in the current reporting period, select Yes and continue with question 45.

If tests were not performed to detect persistence of the cellular therapy product in the current reporting period, select No and continue with question 66.

Question 45: Was persistence evaluated by molecular assay (PCR)?

Molecular assessment involves testing blood, bone marrow, tumor or other source for the presence of known molecular markers. Molecular assessments are the most sensitive test and involve amplifying regions of cellular DNA by polymerase chain reaction (PCR), typically using RNA to generate complementary DNA through reverse transcription (RT-PCR). The amplified DNA fragments are compared to a control, providing a method of quantifying log increase of genetic mutation transcripts. Each log increase is a 10-fold increase of gene transcript compared to control.

Indicate Yes or No whether molecular assay testing was performed to detect the persistence of the genetically modified cellular therapy product within the reporting period. If persistence was not evaluated by molecular assay, report No and continue with question 50.

Question 46: Date Sample collected:

Report the date (YYYY-MM-DD) the sample was collected for molecular assay. If multiple tests were performed in the reporting period and

- all tests were negative, report the date of the first negative test result
- there were positive and negative results, report the date of the last positive test (do not report negative results)

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for
more information on reporting partial and unknown dates.

Questions 47-48: Specify the cell source: (check all that apply)

Specify the cell source of the sample collected for evaluation by molecular assay. Select all that apply. If multiple cell sources were used and persistence was detected in some but not all the samples, report ONLY the cell sources that were positive. If Other source is selected, specify the source in question 48.

Question 49: Were the infused cells detected?

Indicate Yes or No if the infused cells were detected by molecular assay.

Question 50: Was persistence evaluated by flow cytometry testing (immunophenotyping)?

Flow cytometry is a technique that can be performed on blood, bone marrow, or tissue preparations where cell surface markers can be quantified on cellular material. The nature of flow cytometry is to detect cells based on a specific probe. To report flow cytometry results, the test must have been performed to specifically detect the genetically modified cellular therapy product.

Indicate Yes or No if flow cytometry testing was performed to detect the persistence of the genetically modified cellular therapy product within the reporting period. If flow cytometry was not performed, select No and continue with question 55.

Question 51: Date sample collected:

Report the date (YYYY-MM-DD) the sample was collected for flow cytometry testing (immunophenotyping). If multiple tests were performed in the reporting period and

  • all tests were negative, report the date of the first negative test result
  • there were positive and negative results, report the date of the last positive test (do not report negative results)

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

Question 52-53: Specify the cell source (check all that apply)

Specify the cell source of the sample collected for evaluation by flow cytometry. Select all that apply. If multiple cell sources were used and persistence was detected in some but not all the samples, report ONLY the cell sources that were positive. If Other source is selected, specify the source in question 53.

Question 54: Were the infused cells detected?

Indicate Yes or No if the infused cells were detected by flow cytometry testing (immunophenotyping).
**Question 55: Was persistence evaluated by immunohistochemistry?**

Immunohistochemistry is a process that uses antibodies to test for certain antigens (markers) in a sample. When the antibodies bind to the antigen in the tissue sample, the enzyme or dye is activated, and the antigen can then be seen under a microscope.

Indicate **Yes** or **No** if immunohistochemistry testing was performed to detect the persistence of the genetically modified cellular product within the reporting period. If immunohistochemistry testing was not performed in the current reporting period, report **No** and continue with question 60.

**Question 56: Date sample collected:**

Report the date (YYYY-MM-DD) the sample was collected for immunohistochemistry studies. If multiple tests were performed in the reporting period and

- all tests were negative, report the **date of the first negative test result**
- there were positive and negative results, report the **date of the last positive test (do not report negative results)**

If the exact date is unknown, please view [General Instructions, General Guidelines for Completing Forms](#) for more information on reporting partial and unknown dates.

**Question 57-58: Specify the cell source:**

Specify the cell source of the sample collected for evaluation by immunohistochemistry. Select all that apply. If multiple cell sources were used and persistence was detected in some but not all the samples, report **ONLY** the cell sources that were positive. If **Other source** is selected, specify the source in question 52.

**Question 59: Were the infused cells detected?**

Indicate **Yes** or **No** if the infused cells were detected by immunohistochemistry testing.

**Questions 60-61: Was persistence evaluated by other method?**

Indicate **Yes** or **No** if persistence of cells was tested by a method not listed above. If **Yes**, specify the other method used to evaluate persistence of cells in question 61. If persistence of cells was not tested by another method, select **No** and continue with question 66.

**Question 62: Date sample collected:**

Report the date (YYYY-MM-DD) the sample was collected for the other method. If multiple tests were performed in the reporting period and

- all tests were negative, report the **date of the first negative test result**
- there were positive and negative results, report the **date of the last positive test (do not report negative results)**
If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

**Question 63-64: Specify the cell source:**

Specify the cell source of the sample collected for evaluation by other method. Select all that apply. If multiple cell sources were used and persistence was detected in some but not all the samples, report ONLY the cell sources that were positive. If Other source is selected, specify the source in question 64.

**Question 65: Were the infused cells detected?**

Indicate Yes or No if the infused cells were detected by other method.

**Question 66: Were B-cell counts monitored after infusion?**

CAR-T cells that target antigens (CD19, CD20, CD22, BCMA) on B-cells do not distinguish between cancerous and normal B-cells. As result, the recipient can develop B-cell aplasia (low number or absence of B-cells). B-cell aplasia can be used as a surrogate to track persistence of the product. If the recipient has B-cell aplasia, then the product may still be present.

Indicate Yes or No if B-cell counts were monitored during the current reporting period. If B-cell counts were not monitored, select No and continue with question 69.

**Question 67: Was there B-cell recovery?**

A guideline for B-cell aplasia is a B-cell count of < 50 cells/µL of blood. If B-cell aplasia was identified and B-cells subsequently recovered (>50 cells/uL), select Yes. If B-cells never recovered, report No and continue with question 69.

B-cell counts in the blood do vary with age, and children have much higher counts than adults. The younger the child, the higher is the concentration.

**Question 68: Date of B-cell recovery**

Report the date (YYYY-MM-DD) the flow cytometry report showed B-cell recovery.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

Last modified: Sep 23, 2022
**Q69-79: Graft vs. Host Disease**

*Autologous Infusions*
Questions 68-89 should be completed for allogeneic infusions only. If this was an autologous infusion, continue to the “Toxicities” section.

**Combined follow up**
In scenarios where both HCT and cellular therapy forms are being completed, there are duplicate questions across the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450) forms and the Cellular Therapy Essential Data Follow-Up (4100) form. To reduce the reporting burden, duplicate questions, including GVHD, on the Cellular Therapy forms are disabled and will be answered on the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450) form.

Graft versus Host Disease (GVHD) is an immunological phenomenon resulting from the reaction of donor immune cells against major or minor histocompatibility antigens of the recipient. GVHD is primarily caused by donor-derived T-cells. Very rarely, GVHD may occur due to autologous reactivity (autologous GVHD), third party transfusions, or with identical twin transplantation.

Factors influencing the severity of GVHD are related to three main categories: 1) donor or graft, 2) recipient, and 3) treatment. The most influential donor/graft factor is the degree of genetic disparity between the donor and the recipient (HLA match), but other risk factors include female donor to male recipient, donor parity, older donors, and T-cell dose. The occurrence of acute GVHD becomes a risk factor for the development of chronic GVHD. Recipient age and prior infections are also factors.

In the past, GVHD was classified as acute or chronic based on its time to diagnosis following transplant, and other clinical and histological (biopsy or post-mortem) features. Today, there has been increased recognition that acute and chronic GVHD are not dependent upon time since infusion, so determination of acute or chronic should rest on clinical and histologic features. However, organ staging, and overall grade should only be calculated from the clinical picture, not histology. Acute GVHD usually begins between 10 and 40 days after HCT but can appear earlier or later. The organs most commonly affected by acute GVHD are the skin, gut, or liver. Other sites, such as the lung, may be involved.

*Acute / Chronic GVHD*
If acute GVHD is diagnosed prior to chronic GVHD, report the diagnosis information, maximum severity of any symptoms, and treatment administered up to the date of diagnosis of chronic GVHD in the acute GVHD section of the form (questions 69-80). Do not include any signs, symptoms, or treatment occurring on or after the onset of chronic GVHD when completing the acute GVHD section. Report any new or persistent acute GVHD symptoms occurring on or after the onset of chronic GVHD only in the chronic GVHD section of the form (questions 81-86). If chronic GVHD was diagnosed in a prior reporting period, report “no” for questions 69 and 71 in each subsequent reporting period. See reporting scenarios included in question 69.
**Question 69: Did acute GVHD develop since the date of last report?**

Questions 69 and 71 on the Cellular Therapy Essential Data Follow-Up Form are meant to capture whether the recipient had active symptoms of acute GVHD during the reporting period. If the recipient had active acute GVHD during the reporting period, either question 69 or question 71 must be answered **Yes** unless there has been a prior / concurrent diagnosis of chronic GVHD (see note above question 69). There will not be a situation where Yes is reported for both question 69 and question 71. If question 69 is answered yes and a diagnosis date has been reported in question 70, question 71 will be disabled in FormsNet3SM. Centers should report Yes for question 69 to indicate the recipient developed acute GVHD in the following scenarios:

- Acute GVHD is diagnosed for the first time during the reporting period
- An acute GVHD flare is diagnosed during the current reporting period and all of the following conditions are met:
  - The recipient’s prior acute GVHD symptoms did not persist from the prior reporting period into the beginning of current reporting period.
  - The flare is diagnosed after at least 30 days without any active acute GVHD symptoms.
  - The recipient was not diagnosed with chronic GVHD on or before the date of the flare (see note above question 69).

If the recipient does have active acute GVHD during the reporting period, but does not match either of the scenarios above, the center will likely need to report **No** for question 69 and **Yes** for question 71. Question 71 is intended to capture acute GVHD which has continued from a prior reporting period. This includes any flares which do not meet the above conditions. The intent of classifying GVHD episodes as newly developed or persistent is to avoid having centers re-report diagnosis information which has been captured on a prior form. Refer to the Acute GVHD diagnosis scenarios below to see examples of how to answer questions 69 and 71.

Report **No** for questions 69 and 71 if the recipient had no active acute GVHD symptoms during the reporting period **OR** all acute GVHD signs / symptoms during the reporting period occurred after a diagnosis of chronic GVHD (see note above question 69).

Indicate **Unknown** if there is no information about the recipient’s GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

**Acute GVHD Diagnosis Scenarios:**

**A.** A recipient receives a cellular therapy infusion of an allogeneic product on 1/1/2015 and develops acute GVHD which is clinically diagnosed on 2/1/2015. At least one of their symptoms, attributed to acute GVHD, persists beyond the 100 day date of contact which is 4/5/2015. Treatment continues and symptoms completely resolve on 5/1/2015. Immunosuppression is tapered until a flare of acute GVHD is diagnosed on 5/25/2015. Immunosuppression is given and symptoms quickly resolve with no active acute GVHD beginning 6/10/2015. The six month date of contact is 6/20/2015. Another flare of acute GVHD is clinically diagnosed on 8/15/2015.
100 Day Post-TED Form:
Question 69: Report Yes to indicate a new clinical diagnosis of acute GVHD.
Question 70: Report the initial date of diagnosis (2/1/2015).
Question 71: Leave blank. This question will be skipped whenever a diagnosis date has been entered in question 70.
Questions 72-78: Answer these questions based on the assessments performed at the time of diagnosis (2/1/2015).

Six Month Post-TED Form:
Question 69: Report No to indicate acute GVHD persists from a previous report. Note, the flare of acute GVHD was < 30 days from symptoms resolution so it doesn’t count as a new reportable episode.
Question 70: Leave blank. This question will be skipped whenever question 69 is answered “no.”
Question 71: Report Yes to indicate GVHD persists from a previous report.
Questions 72-78: Leave blank. Answering Yes for question 71 prevents the center from re-reporting diagnosis information already captured on the 100 day form.

One Year Post-Infusion Data Form:
Question 69: Report Yes to indicate a flare of acute GVHD occurred at least 30 days after resolving during a prior reporting period.
Question 70: Report the diagnosis date of the flare occurring during the reporting period (8/15/2015).
Question 71: Leave blank. This question will be skipped whenever a diagnosis date has been entered in question 70.
Questions 72-78: Answer these questions based on the assessments performed at the time of diagnosis of the flare of acute GVHD (8/15/2015).

B. A recipient receives a cellular therapy infusion of an allogeneic product on 1/1/2015 and develops acute skin GVHD on 2/1/2015 and then chronic eye GVHD on 3/1/2015. Both acute and chronic symptoms resolve by the 100 day date of contact (4/5/2015). While tapering their immunosuppression, the recipient has a flare of their acute skin GVHD on 5/30/2015. Treatment continues and symptoms completely resolve by the six month date of contact (6/20/2015).

100 Day Post-Infusion Data Form:
Question 69: Report Yes to indicate a new clinical diagnosis of acute GVHD.
Question 70: Report the initial date of diagnosis (2/1/2015).
Question 71: Leave blank. This question will be skipped whenever a diagnosis date has been entered in question 70.
Questions 72-78: Answer these questions based on the assessments performed at the time of diagnosis (2/1/2015).

Six Month Post-Infusion Data Form:
Question 69: Report No to indicate acute GVHD did not develop during the reporting period.
Question 70: Leave blank. This question will be skipped whenever question 69 is answered No
Question 71: Report No to indicate acute GVHD did not persist from a previous report.

If chronic GVHD has been diagnosed in a prior reporting period, report “no” for questions 69 and 71. Any
new or persistent acute GVHD symptoms occurring after the onset of chronic GVHD must be reported in the chronic GVHD section of the form. Do not include any signs, symptoms, or treatment occurring on or after the onset of chronic GVHD when completing the acute GVHD section. This instruction has been provided in the note above question 69.

Question 70: Date of acute GVHD diagnosis:

Report the date of clinical diagnosis of acute GVHD. The clinical diagnosis date may not necessarily be the date the symptoms began (example: the recipient developed a rash one week prior to the physician clinically diagnosing acute skin GVHD). If the clinical diagnosis is documented, but the diagnosis date is unclear, obtain documentation from the primary physician confirming the clinical diagnosis date.

If the recipient developed more than one episode of acute GVHD in the same reporting period, report the date of onset of the first episode of acute GVHD.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

Question 71: Did acute GVHD persist since the date of last report?

Question 71 will only be enabled in FormsNet3 if the center has reported No for question 69 and, therefore, has not reported a date of diagnosis in question 70. If prompted to answer question 71, report Yes if acute GVHD was diagnosed in a prior reporting period and any of the following conditions are met:

- The recipient’s acute GVHD symptoms have been active since diagnosis and continue to be active during the current reporting period (i.e., no period of resolution or quiescence since diagnosis).
- The recipient’s acute GVHD symptoms had resolved before the first day of the current reporting period, but a flare occurred within 30 days of symptom resolution / quiescence.
- The recipient was not diagnosed with chronic GVHD on or before the date of the flare (see note above question 69).

Report No for questions 69 and 71 if the recipient had no active acute GVHD symptoms during the reporting period or all acute GVHD signs / symptoms during the reporting period occurred after a diagnosis of chronic GVHD (see note above question 69).

Indicate Unknown if there is no information about the recipient’s GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

Question 72: Overall grade of acute GVHD at diagnosis:

Indicate the overall grade of acute GVHD at the time of diagnosis. The acute GVHD grading scale is based on clinical evidence (physician observation), not histology. Pathology reports sometimes list a histologic grade of GVHD. Do not report the histologic grade. GVHD scoring and grading is based on clinical severity, not histologic severity. Biopsy of affected organs allows for more precise diagnosis as to the presence or absence of GVHD. However, overall grading remains clinical and is based on the criteria published by
Przepiorka et al., Bone Marrow Transplant 1995; 15(6):825-8, see the GVHD Grading and Staging table below.

If acute GVHD was present, but the grade at diagnosis was not documented and it cannot be determined from the grading and staging table, report Not applicable.

Examples may include:

- Only elevated liver function tests without increased bilirubin
- Any other organ involvement without skin, liver, or gut symptoms attributable to GVHD
- Lower intestinal tract involvement where the stage cannot be determined in select scenarios (see lower intestinal tract involvement description below)

**Upper GI GVHD**

If the recipient only has upper GI GVHD during the reporting period, report this as overall grade II. This may differ from prior instructions regarding how to report upper GI GVHD.
**GVHD Grading and Staging**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Skin</th>
<th>Liver</th>
<th>Gut</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Rash on &lt;25% of skin</td>
<td>Bilirubin 2-3 mg/dl³</td>
<td>Diarrhea &gt; 500 ml/day³ or persistent nausea³</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pediatric: 280-555 ml/m²/day or 10-19.9 mL/kg/day</td>
</tr>
<tr>
<td>2</td>
<td>Rash on 25-50% of skin</td>
<td>Bilirubin 3-6 mg/dl</td>
<td>Diarrhea &gt;1000 ml/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pediatric: 556-833 ml/m²/day or 20-30 mL/kg/day</td>
</tr>
<tr>
<td>3</td>
<td>Rash on &gt;50% of skin</td>
<td>Bilirubin 6-15 mg/dl</td>
<td>Diarrhea &gt;1500 ml/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pediatric: &gt;833 ml/m²/day or &gt; 30 mL/kg/day</td>
</tr>
<tr>
<td>4</td>
<td>Generalized erythoderma with bullous formation</td>
<td>Bilirubin &gt;15 mg/dl</td>
<td>Severe abdominal pain with or without ileus</td>
</tr>
</tbody>
</table>

**Grade⁵**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Skin</th>
<th>Liver</th>
<th>Gut</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Stage 1-2</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>II</td>
<td>Stage 3</td>
<td>Stage 1</td>
<td>Stage 1</td>
</tr>
<tr>
<td>III</td>
<td>—</td>
<td>Stage 2-3</td>
<td>Stages 2-4</td>
</tr>
<tr>
<td>IV⁶</td>
<td>Stage 4</td>
<td>Stage 4</td>
<td>—</td>
</tr>
</tbody>
</table>

1. Use “Rule of Nines” ([Percent Body Surfaces table](#)) or burn chart to determine extent of rash.

2. Range given as total bilirubin. Downgrade one stage if an additional cause of elevated bilirubin has been documented.

3. Volume of diarrhea applies to adults. For pediatric patients, the volume of diarrhea should be based on body surface area. Downgrade one stage if an additional cause of diarrhea has been documented.

4. Persistent nausea with or without histologic evidence of GVHD in the stomach or duodenum.

5. Criteria for grading given as minimum degree of organ involvement required to confer that grade. Grade IV may also include lesser organ involvement with an extreme decrease in performance status.

**Question 73-79: List the stage for each organ at diagnosis of acute GVHD:**

Skin: Select the stage that reflects the body surface area involved with a maculopapular rash attributed to acute GVHD at the time of acute GVHD diagnosis or flare in the reporting period. See the Percent Body Surfaces table below to determine the percent of body surface area involved with a rash. Do not report ongoing rash not attributed to acute GVHD at the time of acute GVHD diagnosis or flare.

**Percent Body Surfaces**
**Body Area** | **Percent** | **Total Percentage**
---|---|---
Each Arm | 9% | 18%
Each Leg | 18% | 36%
Chest & Abdomen | 18% | 18%
Back | 18% | 18%
Head | 9% | 9%
Pubis | 1% | 1%

**Lower intestinal tract (use mL/day for adult recipients and mL/m²/day for pediatric recipients):** Select the stage that reflects the volume of diarrhea attributed to acute GVHD at the time of acute GVHD diagnosis or flare in the reporting period. Use mL/day for adult recipients and mL/m²/day for pediatric recipients. Input and output records may be useful in determining the volume of diarrhea. Do not report ongoing diarrhea not attributed to acute GVHD at the time of acute GVHD diagnosis or flare.

If diarrhea is attributed to acute GVHD during the reporting period, but the volume of stool output is not documented, report “stage 0” for lower intestinal tract involvement. In this case, report “not applicable” for the overall grade unless stage 4 acute skin GVHD, stage 4 acute liver GVHD, or an extreme decrease in performance status was also documented at the time point being reported (at diagnosis or maximum grade during the reporting period). Report an overall grade of IV if stage 4 acute skin GVHD, stage 4 acute liver GVHD, or an extreme decrease in performance status is documented at the time point being reported (see GVHD Staging and Grading Table). Report overall grade III if stage 2-3 liver involvement is documented at the time point being reported and there is no evidence of grade IV GVHD.

**Upper intestinal tract:** Select the stage that reflects the presence of persistent nausea or vomiting attributed to acute GVHD at the time of acute GVHD diagnosis or flare in the reporting period. Do not report ongoing nausea or vomiting not attributed to acute GVHD at the time of acute GVHD diagnosis or flare.

**Liver:** Select the stage that reflects the bilirubin level attributed to acute GVHD at the time of acute GVHD diagnosis or flare in the reporting period. Do not report ongoing hyperbilirubinemia not attributed to acute GVHD at the time of acute GVHD diagnosis or flare.

For recipients who have a normal bilirubin level with elevated transaminase levels attributed to acute GVHD, report this in questions 77-78 “Other site(s) involved with acute GVHD”.

**Other site(s) involved with acute GVHD:** Indicate whether acute GVHD affected an organ other than skin, upper GI, lower GI, or liver manifesting with hyperbilirubinemia. This includes transaminitis attributed to acute GVHD. Report only other organ involvement at the time of acute GVHD diagnosis or flare in the reporting period. Do not report symptoms ongoing but not attributed to acute GVHD at the time of acute GVHD diagnosis or flare. Specify the other organ system involvement in question 78. If reporting transaminitis under Other site, write in “transaminitis” rather than “liver” when specifying the site. This will
prevent queries regarding incorrectly reporting liver GVHD (with bilirubin elevation) under “other site.”

**Question 79: Maximum Overall Grade of Acute GVHD:**

Indicate the overall maximum grade of acute GVHD since the date of the last report. Grading is based on clinical evidence (physician observation), not histology. Pathology reports sometimes list a histologic grade of GVHD. Do not report the histologic grade. GVHD scoring and grading is based on clinical severity, not histologic severity. Biopsy of affected organs allows for more precise diagnosis as to the presence or absence of GVHD. However, overall grading remains clinical and is based on the criteria published by Przepiorka et al., Bone Marrow Transplant 1995; 15(6):825-8; see the GVHD Grading and Staging table above.

If chronic GVHD was diagnosed during the reporting period, report the maximum severity of acute GVHD prior to the onset of chronic GVHD. See question 69 for further instructions. Acute GVHD grading scenario D below has been provided for further clarification.

Report the recipient’s maximum acute GVHD grade in the reporting period; this may differ from the grade at diagnosis or may be the same. If acute GVHD was present, but the maximum grade was not documented and it cannot be determined from the grading and staging table, report **Not applicable**.

Examples may include:

- Only elevated liver function tests without increased bilirubin
- Any other organ involvement without skin, liver, or gut symptoms attributable to GVHD
- Lower intestinal tract involvement where the stage cannot be determined in select scenarios (see lower intestinal tract involvement description above)

**Upper GI GVHD**

If the recipient only has upper GI GVHD during the reporting period, report this as overall grade II. This may differ from prior instructions regarding how to report upper GI GVHD.

**Acute GVHD Grading Scenarios:**

**A.** A recipient developed stage 2 skin involvement and elevated liver function tests (LFTs) attributed to acute GVHD; however, there was no total bilirubin manifestation. In this case, overall maximum grade I acute GVHD should be reported since the staging / grading can be determined using the GVHD Grading and Staging table above.

**B.** A recipient developed acute liver GVHD with elevated LFTs (i.e., transaminases) with no total bilirubin manifestation. The progress notes indicate stage 1 (grade II overall) acute GVHD of the liver. In this case, the clinical manifestations do not fit the criteria used in the GVHD Grading and Staging table above; “not applicable” would be the best option to report.

**C.** A recipient developed stage 2 skin involvement, which showed improvement in response to topical
steroids. However, the recipient then developed hyperbilirubinemia attributed to stage 1 liver involvement; the skin involvement at that time was stage 1. In this case, grade II would be reported (assuming this was the extent of the recipient's acute GVHD in the reporting period).

D. A recipient developed stage 2 skin involvement which resolved in response to topical steroids. Later in the reporting period, the recipient was diagnosed with mild chronic eye GVHD. Shortly thereafter, they were diagnosed with a stage 3 flare of acute skin GVHD. In this case, grade I would be reported. Do not consider any new or persistent acute GVHD symptoms occurring after the onset of chronic GVHD when completing the acute GVHD section of the form.

**Question 80: Date maximum overall grade of acute GVHD**

Report the date (YYYY-MM-DD) of maximum acute GVHD involvement, based on clinical grade. If the recipient had multiple instances in which their GVHD reached the same maximum grade, report the earliest date. If Not applicable was reported for question 79, question 80 must be left blank.

**Question 81: Did chronic GVHD develop since the date of last report?**

Indicate whether a new clinical diagnosis of chronic GVHD was documented during the reporting period. If chronic GVHD was diagnosed during the reporting period, report Yes and continue with question 82.

If the recipient had a flare of chronic GVHD occurring after at least a 30 day period of symptom quiescence, report Yes and continue with question 82. Report No if symptoms resolve or become quiescent prior to the date of last report and then flare within 30 days. This should be reported as persistent chronic GVHD which is captured in question 83.

Report No if chronic GVHD was not clinically diagnosed – initially or as a flare – in the reporting period; this includes instances where chronic GVHD persists from a prior reporting period without flare in the current reporting period.

Indicate Unknown if there is no information about the recipient's GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

**Question 82: Date of chronic GVHD diagnosis:**

Report the date (YYYY-MM-DD) of clinical diagnosis of chronic GVHD. The clinical diagnosis date may not necessarily be the date the symptoms began (example: the recipient developed shortness of breath one month prior to the clinical diagnosis of pulmonary chronic GVHD). If the clinical diagnosis is documented, but the diagnosis date is unclear, obtain documentation from the primary physician confirming the clinical diagnosis date.

If the recipient developed more than one episode of chronic GVHD in the same reporting period, report the date of onset of the first episode of chronic GVHD.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for
more information on reporting partial and unknown dates.

**Question 83: Did chronic GVHD persist since the date of last report?**

Question 83 will only be enabled in FormsNet3 if the center has reported **No** for question 81 and, therefore, has not reported a date of diagnosis in question 82. Indicate whether chronic GVHD was clinically diagnosed during a previous reporting period and persisted, with active symptoms, into the present reporting period. Do not report quiescent or inactive chronic GVHD, or a prior history of GVHD. If **Yes**, continue with question 84; See question 81 for instructions on reporting a chronic GVHD flare.

If the recipient has no active symptoms during the reporting period, report **No** and continue with question 87.

Indicate **Unknown** if there is no information about the recipient’s GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

**Question 84: Maximum grade of Chronic GVHD (according to best clinical judgement):**

Report the maximum chronic GVHD involvement, based on clinical grade, as documented by the recipient’s primary care provider. The intent of this question is to capture the maximum grade based on the best clinical judgment. If the maximum clinical grade is not documented, request documentation from the recipient’s primary care provider.

Indicate **Unknown** if there is no information about the recipient’s GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

**Question 85: Specify if chronic GVHD was limited or extensive:**

The grading system for chronic GVHD is divided into two categories: limited and extensive. Definitions are based on *Sullivan KM, Blood 1981; 57:267*.

Report **Limited** if chronic GVHD includes only localized skin involvement and/or liver dysfunction. Report **Extensive** if any of the following symptoms are attributed to chronic GVHD:

Generalized skin involvement and/or liver dysfunction

- Liver histology showing chronic aggressive hepatitis, bridging necrosis, or cirrhosis
- Involvement of the eye: Schirmer’s test with <5 mm wetting**, or
- Involvement of the salivary glands or oral mucosa, or
- Involvement of any other target organ

**Note:** Schirmer’s test is required if eye involvement is the only symptom of chronic GVHD. If there are other symptoms of chronic GVHD such as lichen sclerosis of the mouth and skin involvement in addition to the eye symptoms, the Schirmer’s test is not required.
**Question 86: Date of maximum grade of chronic GVHD:**

Report the date (YYYY-MM-DD) of maximum chronic GVHD involvement, based on clinical grade. If the recipient had multiple instances in which their GVHD reached the same maximum grade, report the earliest date.

If the exact date is unknown, please view [General Instructions, General Guidelines for Completing Forms](#) for more information on reporting partial and unknown dates.

**Question 87: Is the recipient still taking systemic steroids? (Do not report steroids for adrenal insufficiency or a steroid taper of ≤10 mg/day for adults, <0.1 mg/kg/day for children)**

**Corticosteroids**

Corticosteroids are captured differently depending on whether they are used topically or systemically. Use the following guidelines when determining how to report corticosteroids used to treat GVHD:

- **Topical Creams for Skin:** Do not report topical ointments or creams used to treat skin GVHD including corticosteroid creams such as Triamcinolone or Hydrocortisone.
- **Other Topical Treatments:** Certain corticosteroid treatments are inhaled or ingested but are not absorbed and are therefore considered topical. Examples include beclomethasone and budesonide. Do not consider these medications when answering question 87.
- **Systemic Treatments:** Systemic administration of corticosteroids, including use of prednisone and dexamethasone, should be reported in question 87.

Indicate whether the recipient is still taking immunosuppressive agents to treat or prevent GVHD on the date of contact. Refer to the guidelines included in the question text if the recipient is taking low dose steroids or steroids for adrenal insufficiency.

Indicate **Not applicable** in any of the following scenarios:

- The recipient has never received systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) to treat or prevent GVHD.
- The recipient stopped taking systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) to treat or prevent GVHD in a previous reporting period and did not restart systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) during the current reporting period.

Indicate **Unknown** if there is no information to determine if the recipient is still taking systemic steroids. This option should be used sparingly and only when no judgment can be made about the recipient still receiving treatment for GVHD on the date of contact. If the recipient has died prior to the discontinuation of systemic steroids used to treat or prevent acute and / or chronic GVHD, select **Yes**.

**Question 88: Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?**

Indicate whether the recipient is still taking non-steroidal immunosuppressive agents (including PUVA) to treat or prevent acute and / or chronic GVHD on the date of contact. Descriptions of many
immunosuppressive agents are included below.

If the recipient did not receive non-steroidal immunosuppressive agents to treat or prevent acute and / or chronic GVHD during the reporting period, report Not applicable. Indicate Not applicable in any of the following scenarios:

- The recipient has never received non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD.
- The recipient stopped taking non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD in a previous reporting period and did not restart non-steroidal immunosuppressive agents (including PUVA) during the current reporting period.

Indicate Unknown if there is no information to determine if the recipient is still taking non-steroidal immunosuppressive agents. This option should be used sparingly and only when no judgment can be made about the recipient still receiving treatment for GVHD in the reporting period.

Examples of Immunosuppressive Agents:

**Aldesleukin (Proleukin):** Increases production of several white blood cells including regulatory T-cells. This drug is also known as interleukin-2.

**ALG (Anti-Lymphocyte Globulin), ALS (Anti-Lymphocyte Serum), ATG (Anti-Thymocyte Globulin)**

**ATS (Anti-Thymocyte Serum):** Serum or gamma globulin preparations containing polyclonal immunoglobulins directed against lymphocytes. These drugs are usually prepared from animals immunized against human lymphocytes. Also report the animal source. If “other” is selected, specify the source.

**Azathioprine (Imuran):** Azathioprine inhibits purine synthesis. Usually, it is used at low doses in combination with other treatments.

**Bortezomib (Velcade):** A proteasome inhibitor.

**Cyclosporine (CSA, Neoral, Sandimmune):** Calcineurin inhibitor which decreases cytokine production by T-cells. Usually given for ≥ 3 months.

**Cyclophosphamide (Cytoxan):** Given in high doses near the date of infusion as single agent prophylaxis.

**Extra-corporeal photopheresis (ECP):** The recipient’s blood is removed from the body, exposes to psoralen and ultraviolet light, and re-infused.

**FK 506 (Tacrolimus, Prograf):** Inhibits the production of interleukin-2 by T-cells.

**Hydroxychloroquine (Plaquenil):** Hydroxychloroquine inhibits transcription of DNA to RNA and is commonly used as an anti-malarial drug.

**Interleukin Inhibitor:** Interleukin inhibitors suppress production of white blood cells and are grouped.
according to their target. Examples of IL-2 inhibitors include daclizumab (Zynbryta) and basiliximab (Simulect). Examples of IL-6 inhibitors include tocilizumab (Actemra) and siltuximab (Sylvant).

**In vivo monoclonal antibody:** Antibody preparations that are infused in the recipient following HCT. Specify the antibody used as: anti CD25 (Zenapax, Daclizumab, AntiTAC), alemtuzumab (Campath), entanercept (Enbrel), infliximab (Remicade), and / or rituximab (Rituxan).

**In vivo immunotoxin:** Antibody preparations linked to a toxin that is infused in the recipient following HCT. Specify the immunotoxin.

**Janus Kinase 2 Inhibitors:** Suppress function of T-effector cells. Examples: ruxoloitinib (Jakafi, Jakavi) and tofacitinib (Xeljanz, Jakvinus).

**Methotrexate (MTX) (Amethopterin):** Inhibits the metabolism of folic acid. It is most often used with cyclosporine and is usually for a short duration of time.

**Mycophenolate mofetil (MMF) (CellCept, Myfortic):** Inhibits the de novo pathway used for lymphocyte proliferation and activation.

**Pentostatin (Nipent):** Inhibits adenosine deaminase, which blocks DNA (and some RNA) synthesis.

**Sirolimus (Rapamycin, Rapamune):** Inhibits the response to interleukin-2, blocking the activation of T-cells.

**Tyrosine Kinase Inhibitor (TKI):** Suppress function of tyrosine kinases thereby downregulating the function of many other cellular proteins / processes including fibrosis and inflammation. Examples: imatinib (Gleevec, Glivec), nilotinib (Tasigna), and dasatinib (Sprycel).

**UV Therapy:** UVA or UVB radiation administered to affected areas of the skin in order to suppress proliferation of cells responsible for GVHD.

**PUVA (Psoralen and UVA):** Psoralen is applied or taken orally to sensitize the skin, and then the skin is exposed to UVA radiation.

**UVB:** Broadband- or Narrowband-UVB radiation is applied to the affected areas of the skin.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Last modified: May 17, 2023
Q89-202: Toxicities

**Combined follow up**
In scenarios where both HCT and cellular therapy forms are being completed, toxicities should still be reported when an HCT follows a cellular therapy. It is possible to have CAR-T cell reactivation post-HCT.

**Question 89: Did the recipient experience Cytokine Release Syndrome (CRS)?**

Cytokine Release Syndrome (CRS) is defined by development of a constellation of signs and symptoms that are seen after the infusion of monoclonal antibodies or cellular therapy products. It results from the rapid release of several inflammatory cytokines as a consequence of immune response triggered by a drug (i.e., monoclonal antibody) or cellular product. This rapid cytokine release into the circulation results in fever (must be ≥100.4F or ≥38C), nausea, chills, hypotension, tachycardia, asthenia, headache, rash, sore throat, respiratory failure or death. This section attempts to collect different clinical and laboratory information to understand the severity of this event.

Indicate **Yes** if CRS occurred or persisted into the current reporting period and continue with question 80. Indicate **No** if CRS did not occur or persist into the current reporting period and continue with question 110.

**Question 90: Was the date of diagnosis previously reported?**

If the CRS was diagnosed in a previous reporting period, and the symptoms continue into this reporting period, and the date has already been reported, select **Yes** and continue with question 92. If CRS was not diagnosed in a prior reporting period, report **No** and continue with question 91.

**Question 91: Date of diagnosis:**

Report the date (YYYY-MM-DD) when the first symptom of CRS was documented by a physician or other health care provider in the progress note or chart.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

**Questions 92-94: Specify therapy given for CRS: (check all that apply)**

Check all that apply from the list of the drug(s) given to treat CRS in this reporting period. If **Other therapy** is selected, specify the therapy in question 93.
If Tocilizumab was given to treat the CRS, report the number of doses given in question 94. This information is important in the grading of the CRS event.

Questions 95-105: Indicate symptoms of CRS (check all that apply)

Indicate which symptoms of CRS the recipient experienced in the current reporting period, check all symptoms that apply. For each symptom reported, also report the date of onset. If there were multiple occurrences of a symptom (e.g., fever), report the first occurrence.

If CRS is persisting from a prior reporting period, report the symptoms that worsened or carried over in this reporting period.

**Fever (≥100.4°F or ≥38°C):** A disorder characterized by elevation of the body’s temperature above the upper limit of normal. Do not report fever if less than 100.4°F or 38°C in this field. Fever less than 100.4°F or 38°C does not qualify as a symptom of CRS. Report the date of fever onset in question 87. If there were multiple fevers in the reporting period, report the first occurrence. If the recipient self-reported a fever from a home test, and the date is documented in the medical records, report the date of the home test.

**Hypotension requiring therapy:** Abnormally low blood pressure requiring treatment with volume resuscitation using intravenous isotonic fluids or vasopressors such as norepinephrine, dopamine, dobutamine, epinephrine, phenylephrine, or vasopressin. The use of vasopressors to control blood pressure is an indirect assessment of severity of CRS. Report the date of hypotension onset in question 97. Report therapy given for hypotension in question 98. Examples of what not to report as other therapy include, but are not limited to, antibiotics, corticosteroids, any brand names, hypertension or antiarrhythmic drugs, or any drug used for CRS treatment (e.g. Anakinra, Tocilizumab).

Options for number of vasopressors include 1 or >2 and can be used to determine the grade. One important consideration here is the use of vasopressin, which can be used with fluids or other vasopressors to stabilize the blood pressure. In order to assess severity, only patients who received two or more vasopressor agents at the same time excluding vasopressin, should be marked as >2 vasopressors. Addition of vasopressin to other vasopressor agents does not reflect the same level of acuity compared to a patient requiring 2 or more vasopressors without vasopressin. Only use the option of number of vasopressors as >2 for patients who are receiving multiple vasopressors at the same time excluding vasopressin. Select the number of vasopressors used for therapy in question 100.

Specify any vasopressor(s) used at the same time as a single therapy to treat hypotension in question 101 and 102. And report if hypotension was controlled with therapy in question 103. Controlled means not worsening clinically or resolving the hypotension / managing it without the need for additional agents such as pressors.
**Hypoxia requiring minimal supplemental oxygen (FiO2<40%):** A lower than normal concentration of oxygen in arterial blood requiring supplemental oxygen of <40% FiO2. One example here is the delivery of supplemental oxygen with a low-flow nasal cannula or blow-by device. Report the date of onset in question 104.

**Hypoxia requiring more than minimal supplemental oxygen (FiO2>40%):** A lower than normal concentration of oxygen in arterial blood requiring supplemental oxygen of >40% FiO2. Also specify if positive pressure ventilatory support is required, such as CPAP, BiPAP, intubation or mechanical ventilation. Do not report use of CPAP for sleep apnea. Examples here include the requirement of supplemental oxygen delivered through a high-flow nasal cannula, facemask, opti-flow, non-rebreather mask or Venturi mask. Report the date of onset in question 105.

Source: Common Terminology Criteria for Adverse Events (CTCAE) v5.0

**Questions 106-107: Was positive pressure ventilatory support required (CPAP, BiPAP, intubation, and mechanical ventilation):**

This option outlines the need of devices considered as positive pressure ventilation which could be non-invasive like continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP or BPAP), or invasive, which requires endotracheal intubation with mechanical ventilation.

Patients who use BiPAP or CPAP for obstructive sleep apnea are not considered the same here and should not be reported in this question. The intent of this question is the treatment of respiratory insufficiency or failure.

If positive pressure ventilatory support was required, select **Yes** and report the start date in question 107. If the recipient required multiple types of positive ventilatory support, report the start date of the first method. If positive pressure ventilatory support was not required, or it unknown if it was required, report **No** or **Unknown** and continue with question 108.

**Questions 108-109: Did cytokine release syndrome resolve?**

If the cytokine release syndrome resolved, select **Yes** and report the resolution date (YYYY-MM-DD) in question 109.

If the exact date is unknown, please view [General Instructions, General Guidelines for Completing Forms](#) for more information on reporting partial and unknown dates.

If the cytokine release syndrome did not resolve, select **No** and continue with question 110.

It is possible a patient could experience CRS like symptoms after the CRS event has previously resolved. In these situations, please report the date of onset, the worst grade of both events, and the resolution of the second event if applicable. Please contact CIBMTR Center Support for a review of these types of scenarios.
Questions 110-111: Were there features related to macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH)?

Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) are a severe systematic inflammatory syndromes caused by excessive activation and expansion of T lymphocytes and macrophagic histiocytes. HLH is recognized as both a familial disorder and a sporadic disorder associated with an infection, malignancy, and rheumatologic disorders\(^1\). Diagnostic clinical criteria for MAS/HLH include fever, cytopenias, high triglyceride levels, high ferritin levels, high soluble IL-2 receptor levels, low fibrinogen levels or organomegaly. MAS/HLH has also been reported following chimeric antigen receptor (CAR) T-cell therapy. Some patients may present with CRS and progress into this more aggressive syndrome, where the MAS/HLH falls into the spectrum of CRS. But MAS/HLH may also develop independently which can be due to the recipient's underlying disease (especially lymphoma\(^1\)). The intent of this question is to capture whether MAS/HLH occurred in the recipient regardless of CRS occurring.


Report the date (YYYY-MM-DD) in question 111 when the first symptom of MAS/HLH was documented by either the date of the pathological confirmation of MAS/HLH (bone marrow or other organ biopsy) or the first date of a ferritin level > 100,000 ng/mL among patients without pathologic confirmation but with high clinical suspicion (persistent high fevers, ongoing cytopenias, high triglyceride levels, low fibrinogen levels or organomegaly). Continue with question 112.

Questions 112: Did the recipient have splenomegaly?

Indicate if the recipient had splenomegaly (i.e., abnormal enlargement of the spleen) that could be attributed to MAS/HLH. Splenomegaly is often documented during the physician’s physical assessment of the recipient and represents an abnormal finding. Splenomegaly can also be detected by imaging techniques such as ultrasonography, CT or MRI. Continue with question 113.

Questions 113: Was MAS/HLH confirmed by a bone marrow biopsy?

The pathognomonic feature of MAS is a bone marrow examination that reveals numerous well differentiated macrophages actively phagocytosing hematopoietic cells. MAS is a subset of HLH, and a bone marrow aspirate and biopsy may be performed to look for microscopic evidence of hemophagocytosis as part of the diagnostic work-up for HLH.

Report Yes if a bone marrow biopsy was obtained to confirm MAS/HLH. Report No if a bone marrow biopsy was not obtained to confirm MAS/HLH.

Questions 114-118: Specify the laboratory values collected (check all that apply)

Hypofibrinogenemia and hypertriglyceridemia support the diagnosis of HLH. The laboratory values should be at the time of diagnosis of MAS/HLH.
If **Fibrinogen** is selected in question 114, report the lowest fibrinogen level in question 115 and the date the sample was collected in question 116.

If **Triglyceride** is selected in question 114, report the highest triglyceride level in question 117 and the date the sample was collected in question 118.

**Questions 119-120: Did macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH) resolve?**

If the macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH) resolved, select Yes and report the resolution date (YYYY-MM-DD) in question 120.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

If the macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH) did not resolve, select No and continue with question 121.

**Questions 121: Did the recipient experience neurotoxicity (ICANS)?**

ICANS (Immune effector Cell-associated Neurotoxicity Syndrome) is the development of different neurologic signs and symptoms reported after the infusion of genetically modified lymphocytes. This was initially thought to be part of CRS, but it was also observed in the absence of any other signs of CRS. Neurotoxicity also appears to be a spectrum of signs and symptoms that vary from fine tremors and word finding difficulties to seizure and loss of conscience. This section collects different neurologic signs that have been described after cellular therapy infusions.

Indicate Yes or No if neurotoxicity occurred or persisted in the current reporting period. If neurotoxicity did not occur / persist into the current reporting period or it is not known, select No or Unknown, respectively then continue with question 160.

**Questions 122: Was the date of onset previously reported?**

If the neurotoxicity was diagnosed in a previous reporting period and symptoms continue into this reporting period and the date has already been reported, select Yes and continue with question 124. If neurotoxicity (ICANS) was not diagnosed in a prior reporting period, report No and enter the date of neurotoxicity (ICANS) diagnosis in question 123.

**Question 123: Date of neurotoxicity (ICANS) onset:**

Report the date (YYYY-MM-DD) when the first symptom of neurotoxicity (ICANS) was documented by a physician or other health care provider in the progress note or chart.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.
Questions 124-125: Specify therapy given for neurotoxicity: (check all that apply)

Check all that apply from the list of drug(s) given to treat neurotoxicity (ICANS) in this reporting period. Pulse dose of corticosteroids are intravenous (IV) high doses given intermittently over a short time period. If Other therapy is selected, specify the therapy in question 125.

Question 126: Which cognitive assessment was performed?

The CAR Toxicity (CARTOX) 10-point neurologic assessment assigns one point for each task performed correctly. A score of 10 is normal. These scales assess cognition and the level of encephalopathy more precisely. They include assessments of orientation, naming, writing, and attention with a score associated with each positive answer. Lower scores are associated with a higher level of encephalopathy.

Unresponsive patients score 0 for all scales. Some centers performed these evaluations multiple times a day. These questions attempt to capture the worst score.

The Immune Effector Cell-Associated Encephalopathy (ICE) assessment is a slightly modified version of the CARTOX-10 assessment. It includes an element for command following.

If another assessment was performed, convert to CARTOX or ICE to report here. See question 127 for a conversion of the Cornell Assessment of Pediatric Delirium (CAPD) to CARTOX or ICE.
### Question 127: What was the lowest score? (e.g., CARTOX-10, ICE)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>CARTOX-10 (12)</th>
<th>ICE SCORE (IMMUNE EFFECTOR ENCEPHALOPATHY) ASSESSMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orientation</td>
<td>Orientation to year, month, city, hospital, or President/Prime Minister of country of residence: 6 points</td>
<td>Orientation to year, month, city, or hospital: 4 points</td>
</tr>
<tr>
<td>Naming</td>
<td>Name 3 objects (e.g., point to clock, pen, button): 3 points</td>
<td>Name 3 objects (e.g., point to clock, pen, button): 3 points</td>
</tr>
<tr>
<td>Writing</td>
<td>Ability to write a standard sentence (e.g., Our national bird is the bald eagle): 1 point</td>
<td>Ability to write a standard sentence (e.g., Our national bird is the bald eagle): 1 point</td>
</tr>
<tr>
<td>Attention</td>
<td>Count backwards from 100 by 10: 1 point</td>
<td>Count backwards from 100 by 10: 1 point</td>
</tr>
<tr>
<td>Following Commands</td>
<td></td>
<td>&quot;Show me two fingers,&quot; or, &quot;Close your eyes and stick out your tongue.&quot;.: 1 point</td>
</tr>
</tbody>
</table>


#### Encephalopathy assessment for children age <12 years using the Cornell Assessment of Pediatric Delirium (CAPD)

<table>
<thead>
<tr>
<th>A lower CARTOX / ICE score indicates a higher grade of neurotoxicity (symptom/signs)</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurological assessment score</td>
<td>Mid (7-9)</td>
<td>Moderate (3-6)</td>
<td>Severe (0-2)</td>
<td>Critical' obtunded</td>
</tr>
</tbody>
</table>

When converting CAPD to CARTOX or ICE, report any number in the corresponding range (e.g. CAPD of ≥9, report 0, 1, or 2)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>CARTOX</th>
<th>ICE</th>
<th>CAPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>7-9</td>
<td>7-9</td>
<td>1-8</td>
</tr>
<tr>
<td>Grade 2</td>
<td>3-6</td>
<td>3-6</td>
<td>1-8</td>
</tr>
<tr>
<td>Grade 3</td>
<td>0-2</td>
<td>0-2</td>
<td>≥9</td>
</tr>
</tbody>
</table>

* For symptoms of neurotoxicity (ICANS), report the HIGHEST grade observed in this reporting period.

### Questions 128-158: Indicate the symptoms of neurotoxicity (ICANS) (check all that apply)

**Cerebral edema**: A swelling in the brain caused by the presence of excessive fluid. Specify the type of cerebral edema in question 130, report if the cerebral edema resolved in question 131, and the date of resolution in question 132 (if applicable).

**Cerebral vascular accident (stroke)**: A disorder characterized by a decrease or absence of blood supply...
to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage. Also report the date of onset and the type of stroke. Hemorrhagic stroke occurs when a weakened blood vessel ruptures. Two types of weakened blood vessels usually cause hemorrhagic stroke: aneurysms and arteriovenous malformations (AVMs). Ischemic strokes occur when the arteries to your brain become narrowed or blocked, causing severely reduced blood flow (ischemia). Report the date of onset and type in questions 133 and 134.

Cognitive impairment: A disorder characterized by a conspicuous change in cognitive function. Specify the type of cognitive impairment in question 135, report if the cognitive impairment resolved in question 137, and the date of resolution in question 138 (if applicable). The date of resolution should be the for the category as a whole, e.g., when the last symptom resolved.

- Amnesia: A disorder characterized by systematic and extensive loss of memory
- Cognitive disorder: A disorder characterized by a conspicuous change in cognitive function
- Confusional state: A disorder characterized by a lack of clear and orderly thought and behavior
- Concentration impairment: A disorder characterized by a deterioration in the ability to concentrate
- Encephalopathy: A disorder characterized by a pathologic process involving the brain
- Hallucination: A disorder characterized by a false sensory perception in the absence of an external stimulus
- Leukoencephalopathy: A disorder characterized by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation as determined by neuroimaging (i.e., brain MRI).
- Loss of consciousness: A disorder characterized by a decrease in ability to perceive and respond
- Mental status changes: a change in a person’s mood, behavior, psychomotor skills, and/or cognition
- Non-infective encephalitis: inflammation of the brain not caused by infection
- Psychomotor retardation: slowing of mental and physical activity
- Other cognitive impairment: other decline in mental abilities not included in above options

Depressed level of consciousness: A disruption in how the brain works that causes a change in behavior. This change can happen suddenly or over days and ranges from increased sleepiness to coma. Specify the most severe level in question 139, report if the depressed level on consciousness resolved in question 140, and the date of resolution in question 141 (if applicable).

Motor neuron disorder: neurological disorder effecting motor neurons that control muscle activity. Specify the type of motor neuron disorder in question 142, report if the motor neuron disorder resolved in question 144, and the date of resolution in question 145 (if applicable). The date of resolution should be the for the category as a whole, e.g., when the last symptom resolved.

- Facial weakness/paralysis: weakness or inability to move facial musculature
- Hemiparesis: Weakness on one side of the body (hemiplegic), partial paralysis of the lower limbs (legs), or other sudden loss of connectivity between the CNS and muscles.
- Paraparesis: Weakness on one side of the body (hemiplegic, partial paralysis of the lower limbs (legs), or other sudden loss of connectivity between the CNS and muscles.
- Guillain-Barre syndrome: A disorder characterized by the body’s immune system attacking the
peripheral nervous system causing ascending paralysis
• Myelitis: Inflammation of the spinal cord
• Other motor neuron disorder: other motor neuron disorder not included in above options

Movement disorder: neurologic disorder causing excess movement or lack of voluntary movement. Specify the type of movement disorder in question 146, report if the movement disorder resolved in question 148, and the date of resolution in question 149 (if applicable). The date of resolution should be the for the category as a whole, e.g., when the last symptom resolved.

• Action tremor: A disorder caused by the rapid alternating contraction and relaxation of muscles with the voluntary movement of a muscle and is a common symptom of diseases of the nervous system.
• Ataxia: A disorder characterized by lack of coordination of muscle movements resulting in the impairment or inability to perform voluntary activities
• Cogwheel rigidity: muscular rigidity causing cogwheel jerks to passive movement of limbs
• Dysgraphia: neurologic disorder causing writing disabilities
• Dyskinesia: abnormal, involuntary movements
• Dysmetria: improper accuracy in voluntary movements
• Gait disturbance: A disorder characterized by walking difficulties
• Myoclonus: involuntary and sudden movement of muscle
• Resting tremor: A disorder caused by the rapid alternating contraction and relaxation of muscles (involuntary) while the body is at rest against gravity and is a common symptom of diseases of the nervous system.
• Other movement disorder: other movement disorder not included in above options

Personality change: deviation from the patient’s normal behavior patterns. Specify the type of personality change in question 150, report if the personality change resolved in question 151, and the date of resolution in question 152 (if applicable). The date of resolution should be the for the category as a whole, e.g., when the last symptom resolved.

• Flat affect: lack of emotional expression
• Personality change: A disorder characterized by a conspicuous change in a person’s behavior and thinking
• Other personality change: other personality changes not included in above options

Seizure: Uncontrolled electrical activity in the brain, which may produce a physical convulsion, minor physical signs, thought disturbances or a combination of symptoms. Specify the type of seizure and severity (grade) in questions 154-156. Report the worst type of seizure if multiple types were experienced in a single reporting period.

Speech impairment: neurologic disorder causing disruption of normal speech. Specify the type of speed impairment in question 157 and specify the grade of dysphasia in question 158 (if applicable)

• Dysphasia: The loss of ability to understand or express speech, caused by brain damage.
• Aphasia: Grade 3 dysphasia is defined as aphasia
**Other symptom:** If the recipient experienced a symptom of neurotoxicity not listed above, report here and specify the symptom in question 129.

*Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, Volume 25, Issue 4, April 2019, Pages 625-638*

**Questions 159-160: Did neurotoxicity resolve?**

If the cellular therapy associated neurotoxicity resolved, select Yes and report the resolution date (YYYY-MM-DD) in question 160. Resolution means complete normalization of neurologic function. It is possible that patients might remain with residual neurologic dysfunction which would not qualify as complete resolution of this complication.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

**Other toxicities**

**Questions 161: Hypogammaglobulinemia**

Hypogammaglobulinemia refers to low levels of circulating gammaglobulins, or immunoglobulins, in the blood and often determined by quantitative levels of immunoglobulins G (IgG), A (IgA) and M (IgM), or most commonly IgG only. Levels lower than 600 mg/dL of circulating IgG are considered to be hypogammaglobulinemia. Normal limits of IgG concentration in the blood vary with age. Children ages 4 to 10, levels lower than 500 mg/dL are considered hypogammaglobulinemia. Children younger than four years, as levels of IgG can be much lower and still be within normal ranges for the age, the diagnosis of hypogammaglobulinemia needs to be confirmed with the treating physician.

Hypogammaglobulinemia is common after CAR-T infusions that target CD19+ cells, which produce immunoglobulins. The degree of hypogammaglobulinemia is associated with a higher risk of infection.

**Example 1.** For an adult recipient, IgG levels were below 600 mg/dL pre-cellular therapy infusion and continue to be low post-infusion. This is reported as a toxicity, even though IgG level were below 600 mg/dL pre-infusion.

**Example 2.** For an adult recipient, IgG levels were below 600 mg/dL pre-cellular therapy infusion and continues to be low post-infusion and immunoglobulin replacement therapy (IVIG) was given post-infusion. This is reported as a toxicity, even though IgG level were below 600 mg/dL pre-infusion.

**Example 3.** For an adult recipient, IgG levels were never below 600 mg/dL, but levels were decreasing post-infusion and immunoglobulin replacement therapy (IVIG) was given. This is not reported as a toxicity since the IgG levels were never below 600 mg/dL, even though immunoglobulin replacement therapy was given.

**Example 4.** For an adult recipient, IVIG was administered prophylactically, but IgG levels were never below
600 mg/dL. This is not reported as a toxicity since the IgG levels were never below 600 mg/dL

**Example 5.** For an adult recipient, IgG levels were below 600 mg/dL pre-infusion and immunoglobulin replacement therapy (IVIG) was given pre-infusion. Post-infusion, all IgG values were greater than 600 mg/dL and never dropped below 600 mg/mL. This is not reported as a toxicity since the IgG levels were never below 600 mg/dL after infusion.

If IgG dropped below 600 (or 500 for children ages 4 – 10) in the reporting period, regardless if the IgG was below 600 prior to infusion, or if the IgG was below 600 (or 500 for children ages 4 – 10) and persistent into the current reporting period, report hypogammaglobulinemia developed or persisted in this reporting period, by selecting **Yes**. If hypogammaglobulinemia did not develop in this reporting period, select **No** and continue with question 166.

Report **Unknown** if the IgG levels were not tested in the reporting period and continue with question 166.

**Questions 162: Was the date of onset previously reported?**

If the hypogammaglobulinemia was diagnosed in a previous reporting period, symptoms continue into this reporting period, and the date has already been reported, select **Yes** and continue with question 162. If hypogammaglobulinemia was not diagnosed in a prior reporting period, report **No** and enter the date of hypogammaglobulinemia diagnosis in question 163.

**Questions 163: Date of onset:**

Report the date (YYYY-MM-DD) when the hypogammaglobulinemia was documented by either a physician / health care provider or determined by lab results. Immunoglobulin replacement therapy (IVIG) is not required for the diagnosis of hypogammaglobulinemia

**Example 1.** IgG levels were measures at 450 mg/dL on June 1; however, immunoglobulin replacement therapy (IVIG) was not given and on June 15, IgG levels had dropped to 400, immunoglobulin replacement therapy was given as this time. Report the onset date as June 1.

**Example 2.** IgG levels were measures at 450 mg/dL on May 15, no immunoglobulin replacement therapy (IVIG). Report the onset date as May 15.

**Example 3.** For an adult recipient, IgG levels were below 600 mg/dL pre-cellular therapy infusion and continue to be low post-infusion Report the onset date as first day values are low post-infusion.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

**Questions 164-165: Did hypogammaglobulinemia resolve?**

Hypogammaglobulinemia can be reported as resolved if there are sustained normal levels of IgG in the blood without the need for IVIG infusions for 6 consecutive months.
Example 1. IgG levels were measured at 450 mg/dL on June 1; immunoglobulin replacement therapy (IVIG) was given on June 15. IgG levels were monitored for the next 7 months, and no further immunoglobulin replacement therapy (IVIG) was given. IgG levels went above 600 mg/dL on December 15 and continued to rise. Report the resolution date as the first test result that was greater than 600 mg/dL (December 15).

Example 2. IgG levels were measured at 450 mg/dL on May 15, no immunoglobulin replacement therapy (IVIG) is given. IgG levels were monitored and went above 600 mg/dL on June 3 and normal levels were sustained. Report resolution date as the first test result that was greater than 600 mg/dL (June 3).

Example 3. IgG levels were measured at 450 mg/dL on June 1; immunoglobulin replacement therapy (IVIG) was given on June 15. IgG levels were not monitored, and the recipient has returned to their primary oncologist. In the absence of any testing, the resolution date can be reported as the date 6 months after the last IVIG infusion.

Example 4. For an adult recipient, IgG levels were measured at 450 mg/dL on June 1; immunoglobulin replacement therapy (IVIG) was given on June 15. IgG levels were monitored over the next six and a half months and no further immunoglobulin replacement therapy (IVIG) was given. IgG levels were tested, and measured greater than 600 mg/dL, on November 29 (2.5 months after last IVIG infusion) and December 25 (6.2 months after the last IVIG infusion). The resolution date should be greater than or equal to 6 months after the last IVIG infusion; therefore December 25 should be reported as the resolution date.

Example 5. For an adult recipient, IgG levels were measured at 450 mg/dL on June 1; immunoglobulin replacement therapy (IVIG) was given on June 15. IgG levels were monitored over the next six and a half months and no further immunoglobulin replacement therapy (IVIG) was given. IgG levels were tested, and measured greater than 600 mg/dL, on November 29 (5.5 months after last IVIG infusion). IgG levels were measured at 450 mg/dL on December 25 (6.2 months after the last IVIG infusion). Hypogammaglobulinemia cannot be reported as resolved in this case.

If the hypogammaglobulinemia resolved, select Yes in question 164 and report the resolution date (YYYY-MM-DD) in question 165 as documented by a physician or other health care provider in the progress note or chart.

Questions 166-167: Did recipient require immunoglobulin replacement therapy?

Replacement therapy is given to prevent infections. If the recipient required immunoglobulin replacement therapy (IVIG) regardless of hypogammaglobulinemia that developed post-infusion, select Yes and indicate if the recipient is still requiring the therapy on the contact date for this reporting period. If the last immunoglobulin replacement therapy (IVIG) was given less than 6 months from the date of contact, report Yes unless it’s clearly stated in the medical record that no more immunoglobulin replacement therapy is required.

Questions 168: Tumor lysis syndrome

Tumor lysis syndrome (TLS) is a disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.
Indicate **Yes** or **No** if tumor lysis syndrome developed in the current reporting period. If tumor lysis syndrome did not develop in this reporting period or it's unknown if tumor lysis syndrome developed, select **No** or **Unknown** respectively and continue with question 174.

**Questions 169: Was the date of onset previously reported?**

If the tumor lysis syndrome was diagnosed in a previous reporting period, symptoms continue into this reporting period, and the date has already been reported, select **Yes** and continue with question 170. If tumor lysis syndrome was not diagnosed in a prior reporting period, report **No** and enter the date of tumor lysis syndrome diagnosis in question 169.

**Questions 170: Date of onset:**

Report the date (YYYY-MM-DD) when the tumor lysis syndrome was documented by a physician or other health care provider in the progress note or chart.

If the exact date is unknown, please view [General Instructions, General Guidelines for Completing Forms](#) for more information on reporting partial and unknown dates.

**Questions 171: Grade:**

Report the most severe grade of the tumor lysis syndrome as documented by a physician or other health care provider in the progress note or chart.

- **Grade 3**: Present
- **Grade 4**: Life-threatening consequences: urgent intervention indicated
- **Grade 5**: Death

**Questions 172-173: Did tumor lysis syndrome resolve?**

If the tumor lysis syndrome resolved, select **Yes** in question 172 and report the resolution date (YYYY-MM-DD) in question 173 as documented by a physician or other health care provider in the progress note or chart.

**Questions 174-175: Other toxicity:**

To reduce the reporting burden, other toxicities reported should be related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.

---

* Reporting multiple other toxicities
  FormsNet3 application: Complete questions 175-179 for each other toxicity by adding additional instance(s) in the FormsNet3 application.
  Paper form submission: Copy question 175-179 and complete for each other toxicity being reported.
If the recipient experienced a toxicity that does not fit in a category above, select Yes and specify the other toxicity in question 175.

If the recipient did not experience other toxicities, select No and continue with question 180.

**Questions 176: Was the date of onset previously reported?**

If the other toxicity was diagnosed in a previous reporting period, symptoms continue into this reporting period, and the date has already been reported, select Yes and continue with question 178. If the other toxicity being reported was not diagnosed in a prior reporting period, report No and enter the date of the other toxicity diagnosis in question 177.

**Questions 177: Date of onset:**

Report the date (YYYY-MM-DD) when the other toxicity was documented by either a physician / health care provider or determined by lab results.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

**Questions 178-179: Did other toxicity resolve?**

Indicate Yes or No if the other toxicity resolved. If Yes, report the resolution date (YYYY-MM-DD) question 179 as documented by a physician or other health care provider in the progress note or chart.

**Questions 180-182: Has the recipient experienced a grade 3 organ toxicity?**

As defined by the CTCAE criteria, grade 3 toxicity represents severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care Activities of Daily Living (ADL), which refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden. If Other is selected, then the grade 3 toxicities / symptoms that are reported should be related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.

Specify the organ affected in question 181.
Specify the toxicity of that organ in question 182. The list of symptoms will dynamically filter based on the organ selected in question 181.

<table>
<thead>
<tr>
<th>Organ / System</th>
<th>Symptom or Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>Capillary leak syndrome, cardiac arrhythmia, hypertension, hypotension, left ventricular systolic dysfunction, myocardial infarction, new or worsening heart failure, pericardial effusion, pericarditis, restrictive cardiomyopathy, thromboembolic event</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Abdominal pain, constipation, diarrhea, dyspepsia (heartburn), gastroenteritis, intestinal obstruction (includes small intestine and colonic), mucositis oral, nausea, vomiting</td>
</tr>
<tr>
<td>Kidneys</td>
<td>Acute kidney injury, chronic kidney disease, cystitis noninfective</td>
</tr>
<tr>
<td>Liver</td>
<td>Alanine aminotransferase increased (ALT), alkaline phosphatase increased, aspartate aminotransferase increased (AST), blood bilirubin increased, hepatic failure, hepatitis</td>
</tr>
<tr>
<td>Lungs</td>
<td>Acute respiratory distress syndrome, dyspnea, productive cough, pulmonary edema, respiratory edema, respiratory failure</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Arthralgia (joint pain), muscle weakness, generalized or specific area (not due to neuropathy), myalgia (muscle pain)</td>
</tr>
<tr>
<td>Nervous system</td>
<td>Dizziness, encephalopathy, headache, tremor</td>
</tr>
<tr>
<td>Other</td>
<td>Anorexia, chills, dysgeusia (taste alternation), edema limbs, fatigue</td>
</tr>
</tbody>
</table>

**Questions 183: Was the date of onset previously reported?**

If the grade 3 organ toxicity was diagnosed in a previous reporting period, symptoms continue into this reporting period, and the date has already been reported, select *Yes* and continue with question 185. Else select *No* and report the date of grade 3 organ toxicity diagnosis in question 184.

**Questions 184: Date of onset:**

Report the date (YYYY-MM-DD) when the grade 3 organ toxicity was documented by either a physician/health care provider or determined by lab results.

If the exact date is unknown, please view [General Instructions, General Guidelines for Completing Forms](https://cibmtr.org/forms-instruction-manual-1-en) for more information on reporting partial and unknown dates.

**Questions 185-186: Did the grade 3 organ toxicity resolve?**

If the grade 3 organ toxicity resolved, select *Yes* in question 184 and report the date (YYYY-MM-DD) in question 186 as documented by a physician or other health care provider in the progress note or chart.
Questions 187-189: Has the recipient experienced a grade 4 organ toxicity?

As defined by the CTCAE criteria, grade 4 toxicity represents life-threatening consequences and urgent intervention is indicated. If Other is selected, then the grade 4 toxicities / symptoms that are reported should be related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.

Specify the organ affected in question 188.

Specify the toxicity of that organ in question 189. The list of symptoms will dynamically filter based on the organ selected in question 188.

<table>
<thead>
<tr>
<th>Organ / System</th>
<th>Symptom or Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>Capillary leak syndrome, cardiac arrhythmia, hypertension, hypotension, left ventricular systolic dysfunction, myocardial infarction, new or worsening heart failure, pericardial effusion, pericarditis, restrictive cardiomyopathy, thromboembolic event</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Abdominal pain, constipation, diarrhea, dyspepsia (heartburn), gastroenteritis, intestinal obstruction (includes small intestine and colonic), mucositis oral, nausea, vomiting</td>
</tr>
<tr>
<td>Kidneys</td>
<td>Acute kidney injury, chronic kidney disease, cystitis noninfective</td>
</tr>
<tr>
<td>Liver</td>
<td>Alanine aminotransferase increased (ALT), alkaline phosphatase increased, aspartate aminotransferase increased (AST), blood bilirubin increased, hepatic failure, hepatitis</td>
</tr>
<tr>
<td>Lungs</td>
<td>Acute respiratory distress syndrome, dyspnea, productive cough, pulmonary edema, respiratory edema, respiratory failure</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Arthralgia (joint pain), muscle weakness, generalized or specific area (not due to neuropathy), myalgia (muscle pain)</td>
</tr>
<tr>
<td>Nervous system</td>
<td>Dizziness, encephalopathy, headache, tremor</td>
</tr>
<tr>
<td>Other</td>
<td>Anorexia, chills, dysgeusia (taste alternation), edema limbs, fatigue</td>
</tr>
</tbody>
</table>

Questions 190: Was the date of onset previously reported?

If the grade 4 organ toxicity was diagnosed in a previous reporting period and symptoms continue into this
reporting period and the date has already been reported, select **Yes** and continue with question 160. Else select **No** and report the date of grade 4 organ toxicity diagnosis in question 159.

**Questions 191: Date of onset:**

Report the date (YYYY-MM-DD) when the grade 4 organ toxicity was documented by either a physician / health care provider or determined by lab results.

If the exact date is unknown, please view [General Instructions, General Guidelines for Completing Forms](#) for more information on reporting partial and unknown dates.

**Questions 192-193: Did the grade 4 organ toxicity resolve?**

If the grade 4 organ toxicity resolved, select **Yes** in question 192 and report the date (YYYY-MM-DD) in question 193 as documented by a physician or other health care provider in the progress note or chart.

**Questions 194-203: Specify the laboratory values collected (check all that apply)**

- **C-reactive protein:** C-reactive protein (CRP) is a protein produced by the liver and found in the blood. CRP levels increase with tissue injury or trauma, infection or inflammation. CRP is also highly associated with IL-6 levels. Specify the maximum value since the date of the last report in question 195, the date the sample was collected in question 196, and the upper limit of normal for your institution in question 197.

- **Interleukin-6:** Interleukin-6 is a pro-inflammatory cytokine derived from macrophages and endothelial cells that increases synthesis and secretion of immunoglobulins by B lymphocytes. Specify the maximum value since the date of the last report in question 198 and the date the sample was collected in question 199.

- **Soluble interleukin-2 receptor α (sIL2RA or soluble CD25):** Interleukin-2 receptor alpha or CD25 can shed from the surface of cells during inflammatory conditions. This test detects soluble or circulating sIL2RA. Report the maximum value since the date of the last report in question 200 and the date the sample was collected in question 201.

- **Total serum ferritin:** Ferritin is an acute phase reactant and is often found in high concentration in highly inflammatory conditions. Report the maximum value since the date of the last report in question 202 and the date the sample was collected in question 203.
None: None of the specified laboratory tests above were performed

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>164-165</td>
<td>4/6/2023</td>
<td>Modify</td>
<td>Increased the length of time required to report resolution of hypogammaglobulinemia from 3 months to 6 months without the need for IVIG infusions. Added a 5th example.</td>
<td>More clinically accurate</td>
</tr>
<tr>
<td>180-182</td>
<td>2/7/2023</td>
<td>Modify</td>
<td>Added Carvykti™ to the red warning box below question 180: This question will enable only if the commercially available product Kymriah®, Breyanzi™, Abecma®, or Carvykti™ is selected in question 1 and can only be completed on the 100 day and 6 month follow-up forms.</td>
<td>Validation was updated to include Carvykti™.</td>
</tr>
<tr>
<td>92-94</td>
<td>2/3/2023</td>
<td>Modify</td>
<td>Clarified what should not be reported as CRS therapy, highlighting the follow text in a blue box: Supportive care treatments should not be reported as treatment for CRS. Examples of what not to report as other therapy include, but are not limited to, acetaminophen (Tylenol®) albumin, antibiotics, IV fluids, or any brand name or specific corticosteroids administered.</td>
<td>Added for clarification</td>
</tr>
<tr>
<td>187-189</td>
<td>12/12/2022</td>
<td>Modify</td>
<td>Clarified when to report other grade 4 organ toxicities/symptoms: If Other is selected, then the grade 4 toxicities / symptoms that are reported should be related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.</td>
<td>Added for clarification</td>
</tr>
<tr>
<td>180-182</td>
<td>12/12/2022</td>
<td>Modify</td>
<td>Clarified when to report other grade 3 organ toxicities/symptoms: If Other is selected, then the grade 3 toxicities / symptoms that are reported should be related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.</td>
<td>Added for clarification</td>
</tr>
<tr>
<td>95-105</td>
<td>11/15/2022</td>
<td>Modify</td>
<td>Clarified how to report a fever documented from a home test: Fevers (≥100.4F or ≥38C): A disorder characterized by elevation of the body’s temperature above the upper limit of normal. Do not report fever if less than 100.4F or 38C in this field. Fever less than 100.4F or 38C does not qualify as a symptom of CRS. Report the date of fever onset in question 87. If there were CAR-T infusions can be done as out-patient procedures</td>
<td></td>
</tr>
</tbody>
</table>

CIBMTR.org

Forms Instruction Manual - 1_en

Page 1814 of 2043
multiple fevers in the reporting period, report the first occurrence. If the recipient self-reported a fever from a home test, and the date is documented in the medical records, report the date of the home test.

<table>
<thead>
<tr>
<th>Date</th>
<th>Modified/Added</th>
<th>Action</th>
<th>Changes/Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>92-94</td>
<td>10/10/2022</td>
<td>Modify</td>
<td>Clarified what not to report for other CRS therapy (in red): Examples of what not to report as other therapy include, but are not limited to, acetaminophen (Tylenol®) albumin, antibiotics, IV fluids, or any brand name or specific corticosteroids administered.</td>
</tr>
<tr>
<td>95-105</td>
<td>10/10/2022</td>
<td>Modify</td>
<td>Clarified what not to report for other hypotension therapy (in red): Examples of what not to report as other therapy include, but are not limited to, acetaminophen (Tylenol®) albumin, antibiotics, IV fluids, or any brand name or specific corticosteroids administered.</td>
</tr>
<tr>
<td>161</td>
<td>4/11/2022</td>
<td>Add</td>
<td>Additional example added to clarify hypogammaglobulinemia reporting: <strong>Example 5.</strong> For an adult recipient, IgG levels were below 600 mg/dL pre-infusion and immunoglobulin replacement therapy (IVIG) was given pre-infusion. Post-infusion, all IgG values were greater than 600 mg/dL and never dropped below 600 mg/mL. This is not reported as a toxicity since the IgG levels were never below 600 mg/dL after infusion.</td>
</tr>
</tbody>
</table>
Infections occur frequently in recipients of cellular therapy or transplant. Questions 204-208 are intended to capture detailed information on clinically significant infections diagnosed during the reporting period. A single infection may be found on multiple cultures or at multiple sites. Infections may recur following resolution of symptoms and negative testing. Use the instructions provided in this section to determine when an infection should be considered clinically significant, and therefore reported, as well as when to report new and/or recurrent infections.

Do **not** report an infection in the following scenarios:

- A recipient only has a positive antibody result.
- The recipient was symptomatic and treated but COVID-19 diagnostic testing was not performed and/or COVID-19 diagnostic testing was performed and negative.

Do **report** an infection in the following scenarios:

- A recipient has a positive COVID-19 diagnostic result (PCR or antigen) or if treatment was given or if the recipient was asymptomatic.
- A recipient has a positive antibody result and a positive COVID-19 diagnostic test (PCR or antigen).

**Question 204-208: Did the recipient develop a clinically significant infection since the date of the last report?**

Indicate whether the recipient developed a clinically significant bacterial, viral, or fungal infection during the reporting period. For the purpose of this manual, the term “clinically significant” refers to any infection requiring treatment. Surveillance cultures in which normal flora is present and the recipient is asymptomatic do not need to be reported. If no clinically significant infections occurred during the reporting period, report **No** for question 204 and skip to question 209.

Do **not** report the following scenarios:
• Culture-negative neutropenic fever without clear source;
• Upper respiratory infections which are presumed viral, but no virus has been identified;
• Candida detected in oral or stool samples (includes oral thrush);
• Toenail fungus;
• Yeast infection in the groin, vagina, or under the breasts;
• Surveillance cultures in which normal flora is present and the recipient is asymptomatic;
• Infections persisting from a prior reporting period (including infections which have progressed to new sites since the last report); or
• Infections recurring within the time frames specified in the Definitions for Same Infection table below.

If an organism is identified by molecular report, laboratory report, or other physician documentation, the infection should be reported in questions 205-208. If no organism is identified, the center should use the following guidelines to determine whether to report an infection:

• If a fungal infection is suspected (per radiology assessments), but no organism is isolated during the reporting period, report the suspected infection in question 205-208.
• If no particular organism group is identified or suspected, do not report an infection in question 205-208.

For each infection, report the organism, site, and date of diagnosis.

**Definitions for Same Infection**

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Virus</th>
<th>Fungal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>≤ 7 Days</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Any bacteria</td>
<td>• Adenovirus</td>
<td>• Any yeasts</td>
</tr>
<tr>
<td><strong>≤ 30 Days</strong></td>
<td>• Enterovirus</td>
<td>• ≤ 90 Days</td>
</tr>
<tr>
<td>• Clostridium difficile</td>
<td>• Herpes zoster</td>
<td>• Any molds</td>
</tr>
<tr>
<td><strong>≤ 365 Days</strong></td>
<td>• Influenza</td>
<td></td>
</tr>
<tr>
<td>• Helicobacter pylori</td>
<td>• Parainfluenza</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Rhinovirus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Respiratory syncytial</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Varicella zoster</td>
<td></td>
</tr>
<tr>
<td><strong>≤ 30 Days</strong></td>
<td>• Human Herpes Virus - 6</td>
<td></td>
</tr>
<tr>
<td><strong>≤ 60 Days</strong></td>
<td>• Cytomegalovirus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Epstein-Barr virus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Herpes simplex</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Polyomavirus</td>
<td></td>
</tr>
</tbody>
</table>

Based on the timeframes provided above, *same* infection is when the time in-between each positive test is less than the number of days specified for each infection.

**Organism:**
Select the identified or suspected organism as reported on the microbiology report, laboratory report, or other physician documentation.

If the specific organism is not listed, use the code 777 – Other organism and report the name of the organism in the space provided.

In some cases, an infection may be suspected but significant enough to be treated. If a fungal, bacterial, or viral infection is suspected, but not identified, report using code 502 – Suspected bacterial infection, 503 – Suspected fungal infection or 504 – Suspected viral infection. As noted above, only report infections which are clinically significant.

Site:
Infections can occur virtually anywhere. In order to capture sufficient detail without excess burden, there is a list for the potential sites. An infection may occur in more than one site at the same time or at different times.

• If the infection is identified at multiple sites with the same organism and within the recurrence interval to be considered the same infection (Definitions for Same Infection table), please report all sites the organism was identified.
• If the infection is identified at multiple sites with an organism already reported but is outside of the recurrence interval to be considered the same infection, please report as a new infection.

Select the site(s) of the infection from the options provided on the form. Report all sites of infection which were confirmed by microbiology, laboratory report, or other physician documentation during the reporting period. This includes any new sites identified after the date of diagnosis as well as after treatment has been initiated.

For clarification, the following site definitions are provided:

Blood: includes blood obtained from a central IV line, catheter tip, or from a direct needle stick (Peripheral draw). Blood should be the reported site for infections identified in the bone marrow.

Bone: an infection in the bone itself (Osteomyelitis)

CNS: includes CSF (cerebrospinal fluid) specimens as well as abscesses and/or inflammation noted on brain imaging (encephalitis, meningitis)

Eyes: includes infection in any part of the eye (i.e., retinitis)

Genital: includes vagina, penis, perineum, ovaries, scrotum, testes, uterus

GI tract, lower: includes jejunum, ileum, colon, rectum, and stool

GI tract, upper: includes mouth, dentition, esophagus, stomach, and duodenum
**Joints:** includes fibrous connective tissue and cartilage at any site of bone articulation, typically isolated to a single area (i.e., not a diffuse infection) such as the knee, elbow, or shoulder

**Liver/Spleen:** includes the gallbladder and biliary tract

**Lung:** also known as the lower respiratory tract

**Skin, cellulitis:** a spreading bacterial or viral infection of the skin and tissues beneath the skin

**Skin, necrotizing fasciitis:** a severe bacterial infection of the fascia, the tissues that line and separate muscles, which causes extensive tissue death including damage to skin and overlying tissues

**Sinus and/or upper respiratory tract:** all areas from the nose to the throat and sinuses, does not include lungs (report as “Lung”), mouth, or dental infections (report mouth and dental as “GI tract, upper”).

**Urinary tract, lower:** includes urinary tract infections and cystitis (bladder inflammation)

**Urinary tract, upper:** includes the kidneys and ureters

**Date of Diagnosis:**
Report the date of diagnosis of the infection as the collection date for the positive microbiology culture or laboratory report. For suspected fungal infections, enter the date of a radiological test or the date treatment was started as the date of diagnosis. If multiple sites of infection are identified during the reporting period, report the collection date of the first positive microbiology culture or laboratory report.

Copy and complete questions 205-208 to report more than one infection during this reporting period.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

---

**COVID-19 Vaccine**

If the recipient received a COVID-19 vaccine at any time (including pre- or post-infusion) prior to July 2021 (before the COVID-19 vaccine questions were available on the Post-CTED Follow-Up (4100) form), select Yes for question 209 at the first opportunity this form becomes available. When reporting the vaccine data, report the actual date the recipient received the vaccine, even if the date is outside of the reporting window or prior to infusion, override the error as Verified Correct and specify in the comments “Per CIBMTR instructions, report actual vaccine date and verify data field as correct.”

**Question 209: Was a vaccine for COVID-19 (SARS-CoV-2) received since the date of last report?**

Indicate if the recipient received a vaccine for COVID-19 (one dose without a planned second dose, first dose with planned second dose, second dose, third dose, and / or booster) within the current reporting period.

If the recipient did not receive a vaccine for COVID-19 or it is not known if the recipient received a vaccine,
select No or Unknown, respectively, and continue with question 214.

Revaccination Post – Infusion
When vaccines are given post-infusion, the physician should make the determination on whether the doses are part of the primary series of vaccines, third primary dose, boosters, or revaccination. If a recipient receives a new course of COVID-19 vaccines following infusion as revaccination, report the vaccines as a new series. The most up to date CDC COVID-19 vaccine information for immunocompromised people can be found here.

Questions 210-211: Specify vaccine brand:
For the reported dose, specify the vaccine brand the recipient received. If the vaccine brand is not listed, select Other type and specify. If the vaccine brand is unknown, leave the field blank and override the error as Unknown.

Third dose versus Booster dose
To determine between a third dose and a booster dose, seek clinician clarification, as needed, using the guidelines listed below:
Third dose: An additional primary dose required for recipients who did not build enough protection from their primary vaccine series, typically for immunocompromised individuals
Booster dose: Administered to recipients who have enough protection after completing their primary vaccine series but then protection decreases over time
Primary vaccine series:
- Two doses of Pfizer-BioNTech or Moderna
- One dose of Johnson & Johnson’s Janssen

Questions 212: Select dose(s) received (check all that apply)
For the reported dose, specify the vaccine dose the recipient in the current reporting period and specify the date when the dose was received. If the exact date is not known, use the process described in the General Instructions, General Guidelines for Completing Forms and select Date Estimated.

Section Updates:

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/ Remove</th>
<th>Description</th>
<th>Reasoning</th>
</tr>
</thead>
</table>

* COVID-19 Vaccine Doses
FormsNet3SM application: Complete questions 210 – 213 to report all COVID-19 vaccine doses received in the current reporting period by adding an additional instance in the FormsNet3SM application. A separate instance should be added for each dose.
Paper form submission: Copy questions 210 – 213 and complete report all COVID-19 vaccine doses received in the current reporting period. A separate instance should be completed for each dose.
<table>
<thead>
<tr>
<th></th>
<th>Modify</th>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>204-208</td>
<td>4/11/22</td>
<td>Add</td>
<td>Clarification added on reporting COVID-19 infections for subsequent infusions &amp; possible reporting scenarios: <strong>Do NOT report an infection in the following scenarios:</strong> A recipient only has a positive antibody result. The recipient was symptomatic and treated but COVID-19 diagnostic testing was not performed and/or COVID-19 diagnostic testing was performed and negative. <strong>DO report an infection in the following scenarios:</strong> A recipient has a positive COVID-19 diagnostic result (PCR or antigen) or if treatment was given or if the recipient was asymptomatic. A recipient has a positive antibody result and a positive COVID-19 diagnostic test (PCR or antigen).</td>
<td></td>
</tr>
<tr>
<td>204-208</td>
<td>4/11/2022</td>
<td>Add</td>
<td>COVID-19 Reinfection blue box added above Q204-208: Reporting COVID-19 Reinfection: There have been cases of recipients recovering from COVID-19 infection, only to later test positive again. For CIBMTR purposes, a new COVID-19 infection should be reported when a recipient tests positive again &gt;21 days from resolution (resolution defined as no signs or symptoms of infection, or a negative diagnostic test).</td>
<td></td>
</tr>
<tr>
<td>209</td>
<td>4/11/2022</td>
<td>Add</td>
<td>Clarification added in regard to revaccination post-infusion: Indicate if the recipient received a vaccine for COVID-19 (one dose without a planned second dose, first dose with planned second dose, second dose, <em>third dose, and/or booster dose</em>) within the current reporting period. If the recipient did not receive a vaccine for COVID-19 or it is not known if the recipient received a vaccine, select No or Unknown, respectively, and continue with question 214. <strong>Revaccination Post-Infusion:</strong> When vaccines are given post-infusion, the physician should make the determination on whether the doses are part of the primary series of vaccines, third primary dose, boosters, or revaccination. If a recipient receives a new course of COVID vaccines following infusion as revaccination, report the vaccines as a new series. The most up to date CDC COVID-19 vaccine information for immunocompromised people can be found here.</td>
<td></td>
</tr>
<tr>
<td>210-211</td>
<td>4/11/2022</td>
<td>Modify</td>
<td>Updated blue box above Q210-211 how to report multiple vaccine doses: <strong>COVID-19 Vaccine Doses</strong> FormsNet3SM application: Complete questions 210 – 213 to report all COVID-19 vaccine doses received in the current reporting period by adding an additional instance in the FormsNet3SM application. A separate instance should be added.</td>
<td></td>
</tr>
</tbody>
</table>
Paper form submission: Copy questions 210 – 213 and complete report all COVID-19 vaccine doses received in the current reporting period. A separate instance should be completed for each dose.

<table>
<thead>
<tr>
<th>Question</th>
<th>Date</th>
<th>Modification</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>210-211</td>
<td>4/11/2022</td>
<td>Modify/Add</td>
<td>Updated question instructions: For the reported dose, specify the vaccine brand the recipient received. If the vaccine brand is not listed, select Other type and specify. If the vaccine brand is unknown, leave the field blank and override the error as Unknown. Third dose versus Booster dose blue box added above question 210-211: Third dose versus Booster dose: To determine between a third dose and a booster dose, seek clinician clarification, as needed, using the guidelines listed below: Third dose: An additional primary dose required for recipients who did not build enough protection from their primary vaccine series, typically for immunocompromised individuals Booster dose: Administered to recipients who have enough protection after completing their primary vaccine series but then protection decreases over time Primary vaccine series: Two doses of Pfizer-BioNTech or Moderna One dose of Johnson &amp; Johnson’s Janssen. Added for clarification</td>
</tr>
</tbody>
</table>
| 212      | 4/11/2022 | Modify | Updated question instructions: For the reported dose, specify the vaccine dose the recipient in the current reporting period and specify the date when the dose was received Updated to account for the multiple
Q214-215: Pregnancy Status

This section focuses on fertility. This is an important section due to the possibility of some genetically modified cells persisting and possible transmission to the fetus.

If a pregnancy is reported, complete the Pregnancy (3501) Form to answer questions specific to the pregnancy. The option of Previously reported should only be used if the same pregnancy instance has already been reported on a Pregnancy (3501) Form that was created as an unscheduled form ("on demand"). If there is a question regarding use of this option, contact CIBMTR Center Support if there are questions.

**Example 1.** Recipient or recipient’s female partner becomes pregnant at day +68. It is reported at the time the 100-day Form Cellular Therapy Essential Data Follow-Up (4100) form is completed. Question 180 or 181 should be answered as Yes, and the Form 3501 should be completed to report all pregnancy information.

**Example 2.** Recipient or recipient’s female partner becomes pregnant at day +68 and had received a commercially available CAR-T product (e.g., Yescarta®). Per protocol, the pregnancy should be reported at the time of knowledge of the pregnancy. The Form 3501 should be created as an unscheduled form in FormsNet3 and completed in a timely manner. When the 100-day Cellular Therapy Essential Data Follow-Up (4100) form is completed, question 214 or 215 should be answered as Previously reported.

**Example 3.** Recipient or recipient’s female partner becomes pregnant at 1 year and 1 month and had received a commercially available CAR-T product (e.g., Yescarta®). Per protocol, the pregnancy should be reported at the time of knowledge of the pregnancy. The Form 3501 should be created as an unscheduled form in FormsNet3 and completed in a timely manner. The outcome of the first pregnancy does not go to term or does not result in a live birth and another pregnancy event occurs at 1 year and 11 months. It is decided to report the 2nd pregnancy event on the 2 year Cellular Therapy Essential Data Follow-Up (4100) form since it is due. Question 214 or 215 should be answered as Yes to create another Form 3501.

**Question 214: Was the recipient pregnant at any time in this reporting period? (Female Only)**

Indicate Yes or *No *if the female recipient was pregnant at any time during the reporting period. If Yes, complete a Pregnancy (3501) form. See examples above.

**Question 215: Was the recipient’s female partner pregnant at any time in this reporting period? (Male only)**

Indicate Yes or No if the male recipient’s female partner was pregnant at any time during the reporting period. If Yes, complete a Pregnancy (3501) form. See examples above.

**Section Updates:**
<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

Last modified: Sep 23, 2022